AXIM Biotechnologies (AXIM) 10-Q/A 15 Nov 22 2022 Q3 Quarterly report (amended) Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 14, 2022
Cover [Abstract]
Entity Registrant Name	AXIM Biotechnologies, Inc.
Entity Central Index Key	0001514946
Document Type	10-Q/A
Amendment Flag	true
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		186,441,917
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-54296
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	27-4029386
Entity Interactive Data Current	Yes
Entity Address Address Line 1	6191 Cornerstone Court
Entity Address Address Line 2	E. Suite 114
Entity Address City Or Town	San Diego
Entity Address State Or Province	CA
City Area Code	858
Local Phone Number	923-4422
Entity Address Postal Zip Code	92121
Amendment Description	The sole purpose of this Amendment No. 1 to the Quarterly Report on Form 10-Q (the “Form 10-Q”) for the period ended September 30, 2022, is to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 to the Form 10-Q provides the financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language). No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q. Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 163,746	$ 452,963
Prepaid expenses	65,390	163,561
Inventory	20,089	20,089
Total current assets	249,225	636,613
Property and equipment, net of accumulated depreciation	102,069	116,810
Other Assets:
Notes receivable- related party	0	104,268
Patents (net of accumulated amortization of $23,509 and $7,409; respectively)	226,491	242,591
Licenses (net of accumulated amortization of $408,452 and $128,718; respectively)	3,861,548	4,141,282
Security deposit	5,000	5,000
Operating lease right-of-use asset	34,374	76,871
Total other assets	4,127,413	4,570,012
TOTAL ASSETS	4,478,707	5,323,435
Current liabilities:
Accounts payable and accrued liabilities	1,049,828	909,458
Derivative liability - conversion feature	1,995,618	0
Lease liability obligations	34,374	56,871
Due to shareholder	0	180
Due to first insurance funding	53,698	32,873
Convertible note payable (including accrued interest of $0 and $16,919 net of unamortized discount of $0 and $0)	0	1,126,919
Deferred Revenue	29,720
Promissory note (including accrued interest of $-0- and $44,041, respectively) (see note7)	0	454,693
Total current liabilities	3,163,238	2,580,994
Long-term liabilities:
Deferred Revenue	118,965	0
Convertible note payable (including accrued interest of $252,820 and $209,685, respectively) net of unamortized debt discount of $1,629,876 and $605,639, respectively(see note 11)	1,315,353	761,604
Convertible note payable - related party (including accrued interest of $261,537 and $299,037, respectively)	4,261,537	4,299,037
Lease liability obligations	0	20,000
Total long-term liabilities	5,695,855	5,080,641
TOTAL LIABILITIES	8,859,093	7,661,635
STOCKHOLDERS' DEFICIT
Preferred stock, $0.0001 par value, 5,000,000 shares authorized;Series B Convertible Preferred Stock, $0.0001 par value 500,000 shares designated,Series C Convertible Preferred Stock, $0.0001 par value 500,000 shares designated,500,000 and 500,000 shares issued and outstanding, respectively	50	50
Common stock, $0.0001 par value, 300,000,000 shares authorized 185,441,917 and 138,099,981 shares issued and outstanding, respectively	18,545	13,811
Additional paid in capital	58,752,209	51,000,166
Subscription receivable	(60,064)	0
Common stock to be issued	135,000	4,530,000
Accumulated deficit	(63,226,126)	(57,882,227)
TOTAL STOCKHOLDERS' DEFICIT	(4,380,386)	(2,338,200)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 4,478,707	$ 5,323,435

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Patents, accumulated amortization net	$ 23,509	$ 7,409
Licenses, accumulated amortization net	$ 408,452	$ 128,718
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	300,000,000
Common Stock, Shares, Issued	185,441,917	185,441,917
Common Stock, Shares, Outstanding	138,099,981	138,099,981
Preferred Stock, Shares authorized	5,000,000	5,000,000
Convertible note payable
Interest Payable, Current	$ 0	$ 16,919
Interest Payable, Non-current	252,820	209,685
Unamortized debt discount, non-current	1,629,876	605,639
Unamortized discount, current	0	0
Promissory note - related party
Interest Payable, Current	0	44,041
Convertible note payable - related party
Interest Payable, Non-current	$ 261,537	$ 299,037
Convertible Preferred Stock Series B [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares designated	500,000	500,000
Convertible Preferred Stock Series C
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares designated	500,000	500,000
Preferred Stock, Shares Issued	500,000	500,000
Preferred Stock, Shares Outstanding	500,000	500,000

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 1,314	$ 8,127	$ 1,314	$ 55,651
cost of goods sold
Gross profit	1,314	8,127	1,314	55,651
Operating Expenses:
Research and development expenses	29,722	67,263	109,086	216,282
Selling, general and administrative	1,182,768	2,519,527	3,083,349	4,812,790
Amortization of Other Assets	98,612	692,858	295,835	1,333,954
Depreciation and amortization	8,132	6,935	23,451	20,119
Total operating expenses from continuing operations	1,319,234	3,286,583	3,511,721	6,383,145
Loss from continuing operations	(1,317,920)	(3,278,456)	(3,510,407)	(6,327,494)
Other (income) expenses:
Interest income	0	(256)	(256)	(769)
Change in fair value of derivative Liability conversion feature	500,887	0	(418,769)	0
Income from Grants from Government	0	(59,986)	0	(279,981)
Amortization of note discount	46,441	17,456	132,521	220,578
Loss on Extinguishment of Debt	111,818	0	490,641	1,535,264
Interest expense	57,481	56,007	1,629,355	175,915
Total other (income) expenses	716,627	13,221	1,833,492	1,651,007
Loss before provision of income tax	(2,034,547)	(3,291,677)	(5,343,899)	(7,978,501)
Provision for income tax	0		0
Income (loss) from continuing operations	(2,034,547)	(3,291,677)	(5,343,899)	(7,978,501)
Income (loss) from discontinued operations	0	0	0	(4,633)
NET LOSS	(2,034,547)	(3,291,677)	(5,343,899)	(7,983,134)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (2,034,547)	$ (3,291,677)	$ (5,343,899)	$ (7,983,134)
Earning per share from continuing operations
Basic	$ (0.01)	$ (0.03)	$ (0.04)	$ (0.06)
Diluted	(0.01)	(0.03)	(0.04)	(0.06)
Earning per share from discontinued operations
Basic	$ 0	$ 0	$ 0	$ 0
Diluted	$ 0	$ 0	$ 0	$ 0
Earning per share
Basic	$ (0.01)	$ (0.03)	$ (0.034)	$ (0.06)
Diluted	$ (0.01)	$ (0.03)	$ (0.034)	$ (0.06)
Weighted average common shares outstanding - basic and diluted	171,893,796	133,663,974	158,091,581	129,803,948

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Total	Common Stock	Series C, Preferred Stock	Common Stock To Be Issued	Additional Paid-In Capital	Subscription Amount Receivable [Member]	Accumulated Deficit
Balance, shares at Dec. 31, 2020		125,327,579	500,000
Balance, amount at Dec. 31, 2020	$ 1,565,821	$ 12,533	$ 50	$ 201,974	$ 43,201,186	$ 0	$ (41,849,922)
common stock to be issued for purchase of share	168,500			168,500
Common stock issued against common stock to be issued received in py, shares		108,965
Common stock issued against common stock to be issued received in py, amount	0	$ 11		(66,974)	66,963
common stock issued for severance payable of discontinued operations, shares		379,463
common stock issued for severance payable of discontinued operations, amount	225,001	$ 38			224,963
Common stock and warrants issued for cash, shares		1,712,500
Common stock and warrants issued for cash, amount	434,000	$ 171			433,829
stock based compensation- stock options	99,742				99,742
Net loss	(864,536)						(864,536)
Balance, shares at Mar. 31, 2021		127,528,507	500,000
Balance, amount at Mar. 31, 2021	1,628,528	$ 12,753	$ 50	303,500	44,026,683	0	(42,714,458)
Balance, shares at Dec. 31, 2020		125,327,579	500,000
Balance, amount at Dec. 31, 2020	1,565,821	$ 12,533	$ 50	201,974	43,201,186	0	(41,849,922)
Net loss	(7,983,134)
Loss on extinguishment of debt	1,535,264
Balance, shares at Sep. 30, 2021		135,885,104	500,000
Balance, amount at Sep. 30, 2021	4,647,671	$ 13,589	$ 50	4,457,500	50,009,591	0	(49,833,059)
Balance, shares at Dec. 31, 2020		125,327,579	500,000
Balance, amount at Dec. 31, 2020	$ 1,565,821	$ 12,533	$ 50	201,974	43,201,186	0	(41,849,922)
cashless exercise stock options, shares	300,000
Balance, shares at Dec. 31, 2021		138,099,981	500,000
Balance, amount at Dec. 31, 2021	$ (2,338,200)	$ 13,811	$ 50	4,530,000	51,000,166	0	(57,882,227)
Balance, shares at Mar. 31, 2021		127,528,507	500,000
Balance, amount at Mar. 31, 2021	1,628,528	$ 12,753	$ 50	303,500	44,026,683	0	(42,714,458)
Net loss	(3,826,924)						(3,826,924)
Common stock issued for services, shares		1,114,351
Common stock issued for services, amount	776,500	$ 111		(16,000)	792,389
Common stock issued for cash, shares		1,234,113
Common stock issued for cash, amount	249,999	$ 123		(152,500)	402,376
Convertible note and accrued interest converted to common stock, shares		2,647,464
Convertible note and accrued interest converted to common stock, amount	582,707	$ 265			582,442
Other, shares		500,000
Other, amount	0	$ 50			332,450	(332,500)
Stock based compensation - stock options	91,526				91,526
Loss on extinguishment of debt	1,535,264				1,535,264
Balance, shares at Jun. 30, 2021		133,024,435	500,000
Balance, amount at Jun. 30, 2021	1,037,600	$ 13,302	$ 50	135,000	47,763,130	(332,500)	(46,541,382)
common stock to be issued for purchase of share	4,322,500			4,322,500
stock based compensation- stock options	761,810				761,810
Net loss	(3,291,677)						(3,291,677)
Common stock issued for services, shares		1,415,554
Common stock issued for services, amount	1,111,900	$ 142			1,111,758
Common stock issued for cash, shares		1,445,115
Common stock issued for cash, amount	476,726	$ 145			476,581
Loss on extinguishment of debt	0
Subscription Receivable share price adjustment					(103,688)	103,688
Subscription price receivable	228,812					228,812
Balance, shares at Sep. 30, 2021		135,885,104	500,000
Balance, amount at Sep. 30, 2021	4,647,671	$ 13,589	$ 50	4,457,500	50,009,591	0	(49,833,059)
Balance, shares at Dec. 31, 2021		138,099,981	500,000
Balance, amount at Dec. 31, 2021	(2,338,200)	$ 13,811	$ 50	4,530,000	51,000,166	0	(57,882,227)
Common stock issued against common stock to be issued received in py, amount	0	$ 17		(25,000)	24,983
Net loss	(2,086,714)						(2,086,714)
Common stock issued for services, shares		802,115
Common stock issued for services, amount	79,500	$ 80		(100,000)	179,420
Stock based compensation - stock options	188,917				188,917
common stock issued under s-1, shares		4,000,000
common stock issued under s-1, amount	594,870	$ 400			594,470
common stock issued against common stock to be issued purchase of atd, shares		7,000,000
common stock issued against common stock to be issued purchase of atd, amount	0	$ 700		(4,270,000)	4,269,300
Common stock issued against common stock to be issued received in PY, shares		166,667
common stock issued stock purchase agreements, shares		976,870
common stock issued stock purchase agreements, amount	105,000	$ 98			104,902
cashless exercise stock options, shares		282,759
cashless exercise stock options, amount		$ 28			(28)
stock issued on settlement of debt, shares		173,390
stock issued on settlement of debt, amount	32,944	$ 17			32,927
Balance, shares at Mar. 31, 2022		151,501,782	500,000
Balance, amount at Mar. 31, 2022	(3,423,683)	$ 15,151	$ 50	135,000	56,395,057	0	(59,968,941)
Balance, shares at Dec. 31, 2021		138,099,981	500,000
Balance, amount at Dec. 31, 2021	(2,338,200)	$ 13,811	$ 50	4,530,000	51,000,166	0	(57,882,227)
Net loss	(5,343,899)
Loss on extinguishment of debt	490,641
Balance, shares at Sep. 30, 2022		185,441,917	500,000
Balance, amount at Sep. 30, 2022	(4,380,386)	$ 18,545	$ 50	135,000	58,752,209	(60,064)	(63,226,126)
Balance, shares at Mar. 31, 2022		151,501,782	500,000
Balance, amount at Mar. 31, 2022	(3,423,683)	$ 15,151	$ 50	135,000	56,395,057	0	(59,968,941)
Net loss	(1,222,638)						(1,222,638)
Stock based compensation - stock options	182,215				182,215
Loss on extinguishment of debt	154,292				154,292
common stock issued under s-1, shares		6,750,000
common stock issued under s-1, amount	286,385	$ 675			377,950	(92,240)
stock issued on settlement of debt, shares		891,610
stock issued on settlement of debt, amount	64,196	$ 89			64,107
stock issued settlement of claim, shares		3,544,247
stock issued settlement of claim, amount	226,171	$ 354			225,817
Balance, shares at Jun. 30, 2022		162,687,639	500,000
Balance, amount at Jun. 30, 2022	(3,733,062)	$ 16,269	$ 50	135,000	57,399,438	(92,240)	(61,191,579)
Net loss	$ (2,034,547)						(2,034,547)
Other, shares	13,500,000
Loss on extinguishment of debt	$ 111,818
common stock issued under s-1, shares		3,227,638
common stock issued under s-1, amount	171,167	$ 323			138,668	32,176
common stock issued stock purchase agreements, shares		13,861,004
common stock issued stock purchase agreements, amount	350,000	$ 1,386			348,614
stock issued on settlement of debt, shares		5,665,636
stock issued on settlement of debt, amount	348,876	$ 567			348,309
Sock based compensation-stock options	517,180				517,180
Balance, shares at Sep. 30, 2022		185,441,917	500,000
Balance, amount at Sep. 30, 2022	$ (4,380,386)	$ 18,545	$ 50	$ 135,000	$ 58,752,209	$ (60,064)	$ (63,226,126)

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,343,899)	$ (7,983,134)
Less: (Loss) gain from discontinued operations	0	(4,633)
Loss from continuing operations	(5,343,899)	(7,978,501)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Depreciation	23,451	20,119
Stock based compensation	888,313	953,076
Amortization of prepaid insurance/expense	187,562	296,542
Amortization of debt discount	132,521	220,578
Common stock issued for services	79,500	1,904,400
Common Stock issued in settlement of an obligation	230,369
Amortization(impairment) of Intangible Assets	295,834	1,333,954
Loss on conversion of convertible note	122,887
Loss on extinguishment of debt	137,388	1,535,264
Change in fair value of derivative liability	(418,769)
Non-cash interest Expense	1,316,846
Severance cost (Note Receivable waived)	102,387
Changes in operating assets & liabilities:
(increase) decrease in accounts receivable		(770)
Increase in interest receivable	1,701	(182,161)
(Increase) decrease in prepaid expenses	(89,391)	(20,127)
Increase in due to First insurance Funding	80,614
Increase in Deferred revenue inventory	148,685
Increase in accounts payable and accrued expenses	375,180	228,426
Net cash provided by (used in) operating activities from continuing operations	(1,728,821)	(1,689,200)
Net cash provided by (used in) operating activities from discontinued operations	0	(4,633)
Net cash provided by (used in) operating activities	(1,728,821)	(1,693,833)
CASH FLOW FROM INVESTING ACTIVITIES:
Purchase of Property and Equipment	(8,710)	(20,022)
Acquisition of patents		(10,000)
Net cash provided by (used in) investing activities from continuing operations	(8,710)	(30,022)
Net cash provided by (used in) investing activities from discontinued operations	0	0
Net cash provided by (used in) investing activities	(8,710)	(30,022)
CASH FLOW FROM FINANCING ACTIVITIES:
Common stock issued under registration statement on Form S-3	1,052,419	0
Common stock issued under SPA	455,000	1,542,040
repayment of first insurance funding	(59,789)	40,511
Proceeds from common stock to be issued per stock purchase agreement	0	52,500
Proceeds from convertible notes	1,325,000	0
Repayment of convertible notes	(1,243,200)	0
Repayment of Promissory note	(81,116)	(30,000)
Net cash provided by (used in) continuing financing activities	1,448,314	1,605,051
Net cash provided by (used in) discontinued financing activities	0	0
Net cash provided by (used in) financing activities	1,448,314	1,605,051
Net (decrease) increase in cash and cash equivalents	(289,217)	(118,804)
Cash and cash equivalents at beginning of period	452,963	457,181
Cash and cash equivalents at end of period	163,746	338,377
CASH PAID DURING THE PERIOD FOR:
Interest	142,500	0
Income taxes - net of tax refund	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES
Common stock issued against common stock to be issued	125,000	66,974
Acquisition of patents against notes payable and accounts payable	0	240,000
Common stock to be issued for acquisition	0	4,270,000
Common stock issued for severance	64,197	225,000
Common stock issued against subscription receivable	60,064	0
Accrued interest converted to common stock	32,944	0
Common stock issued on cashless exercise of options	28	0
Common stock issued against Common stock to be issued for acquisition	4,270,000	0
Initial derivative liability at issuance of notes	2,641,846	0
Initial debt discount at issuance of notes	1,325,000	0
Promissory note refinanced against convertible note	367,931	0
Common stock issued against settlement of debt	$ 348,876	$ 0

ORGANIZATION

ORGANIZATION	9 Months Ended
	Sep. 30, 2022
ORGANIZATION
NOTE 1: ORGANIZATION	NOTE 1: ORGANIZATION The Company was originally incorporated in Nevada on November 18, 2010, as Axim International Inc. On July 24, 2014, the Company changed its name to AXIM Biotechnologies, Inc. to better reflect its business operations. The Company’s principal executive office is located at 6191 Cornerstone Court E suite 114 San Diego Ca 92121. On August 7, 2014, the Company formed a wholly owned Nevada subsidiary named Axim Holdings, Inc. This subsidiary will be used to help facilitate the anticipated activities planned by the Company. On May 11, 2015 the Company acquired a 100% interest in CanChew License Company a Nevada incorporated licensing Company, through the exchange of 5,826,706 shares of its common stock. In October 2017 the company formed a wholly owned subsidiary in the Netherlands for purposes of holding pharmaceutical licenses as required by the Netherlands regulations and laws. On October 16, 2018, the Company formed a wholly owned disregarded entity Marina Street, LLC as part of improvement of internal control over cash management and bank activities. On March 17, 2020, the Company acquired Sapphire Biotech, Inc., (“Sapphire’) which is research and Development Company that has a mission to improve global cancer care through the development of proprietary therapeutics for inhibiting cancer growth and metastasis. Sapphire is also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. Additionally, with the onset of the COVID-19 pandemic, the Company decided to begin creating COVID-19 rapid diagnostic tools, including multiple first-in-class COVID-19 neutralizing antibody tests and other innovations. Sapphire’s operations are located in the Greater San Diego Area. COVID-19 impact and related risks The ongoing global outbreak of COVID-19, and the various attempts throughout the world to contain it, have created significant volatility, uncertainty and disruption. In response to government directives and guidelines, health care advisories and employee and other concerns, A number of the Company’s employees have had to work remotely from home and those on site have had to follow the Company’s social distance guidelines, which could impact their productivity. COVID-19 could also disrupt the Company’s operations due to absenteeism by infected or ill members of management or other employees, or absenteeism by members of management and other employees who cannot effectively work remotely but who elect not to come to work due to the illness affecting others in the Company’s office or laboratory facilities, or due to quarantines. Because of COVID-19, travel, visits, and in-person meetings related to The Company’s business have been severely curtailed or canceled and the Company has instead used on-line or virtual meetings to meet with potential customers and others. In addition to operational adjustments, the consequences of the COVID-19 pandemic have led to uncertainties related to The Company’s business growth and ability to forecast the demand for its diagnostic testing and resulting revenues. The full extent to which the COVID-19 pandemic and the various responses to it might impact The Company’s business, operations and financial results will depend on numerous evolving factors that are not subject to accurate prediction and that are beyond The Company’s control. Changes to the Company’s Board of Directors On January 4, 2022, Mauricio Gatto Bellora tendered his resignation as a member of the Company’s Board of Directors, and the Company on that date accepted his resignation. Mr. Bellora’s decision to resign was not the result of any disagreement with the Company. On January 6, 2022, the record holder of 500,000 shares of the Company’s Series C Preferred Stock, representing 100% of the 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are entitled to cast a vote for election of up to four Series C Directors, whether by shareholder meeting (annual or special) or by written consent, acting pursuant to Section 78.320 of the Nevada Revised Statutes and Article III, Section 3 of the Company’s Amended and Restated Bylaws, consented by written consent in lieu of a meeting appointing Blake N. Schroeder to fill the director seat vacated by the resignation of Mauricio Javier Gatto Bellora. Mr. Blake N. Schroeder, 42, began his career with a commercial litigation law firm in Salt Lake City, Utah. Beginning in 2008, Schroeder focused on the sale and marketing of natural products and opening international marketplaces to those products. From 2008 to 2014 Mr. Schroeder served in various capacities at MonaVie, LLC developing international business plans and growing international businesses. From August 2014 to February 2016, Mr. Schroeder served as the Chief Operating Officer of for evergreen International, where he was responsible for global operation and sales of the multinational organization, including oversight of a global supply chain. From 2021 to the present, Mr. Schroeder has served as the Chief Executive Officer and Chairman of the Board of Medical Marijuana, Inc. From 2016 to the present, Mr. Schroeder serves as the chief executive officer of Kannaway USA, LLC, a wholly owned subsidiary of Medical Marijuana, Inc. Medical Marijuana, Inc. is one of the Company’s largest shareholders holding approximately 16.4% of the Company’s common stock, as of January 10, 2022. Mr. Schroeder holds a B.S. in Finance from Utah State University and a law degree from Syracuse University College of Law. Changes in the Business On March 7, 2022, the Company announced that is has shifted its focus for its rapid COVID-19 Neutralizing Antibody (“Nab”)(NAb) Test to become For Research Use Only (“RUO”). The test will provide researchers an important tool for COVID-19 research and is not intended for use in diagnostic procedures. The Company has also entered a separation agreement with Empowered Diagnostics, LLC following the FDA recall of Empowered’s products, including the NabNAb test.

ACQUISITION OF INTELLECTUAL PRO

ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC LLC	9 Months Ended
	Sep. 30, 2022
ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC LLC
NOTE 2: ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC, LLC.	NOTE 2: ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC, LLC. AXIM entered into two substantially contemporaneous transactions to acquire patents and 510(K) Licenses from Advanced Tear Diagnostics, LLC (the “Seller”) (collectively, the “Asset Acquisition”) for a total amount of $4,520,000. The first transaction occurred on July 29, 2021, in which AXIM purchased five patents (the “Patents”) from the Seller for $250,000 (which includes assuming and paying $30,000 of the Seller’s liabilities). The bulk of the purchase price ($210,000) was in a note that requires seven equal monthly payments of $30,000, which payment started on September 3, 2021. The second transaction occurred on August 26, 2021, in which AXIM purchased certain eye disease diagnostic technology, which consisted of a 510(K) license for Lactoferrin, a biomarker for dry eye disease and a 510(K) license for IgE, a biomarker for allergic ocular reaction (collectively, the “510(K) Licenses”). The purchase price for the 510(K) Licenses was $4,270,000, which price was paid by issuing to the Seller 7 million shares of AXIM restricted common stock. Together, the Patents and the 510(K) Licenses constitute the acquired technology asset (the “Technology Asset”), which for accounting purposes, are considered one unit of account. We are amortizing the Technology Asset ratably over the 11.54 average remaining life of the Patents. In accordance with FASB’s requirements for accounting for business combinations (FASB Accounting Standards Codification, Topic 805, Business Combinations

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2022
BASIS OF PRESENTATION
NOTE 3: BASIS OF PRESENTATION:	NOTE 3: BASIS OF PRESENTATION: The consolidated financial statements of AXIM Biotechnologies, Inc. (formerly Axim International, Inc.) as of September 30, 2022, and 2021 have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”). Principles of Consolidation The consolidated financial statements include the accounts of Axim Biotechnologies, Inc. and its wholly owned subsidiaries Axim Holdings, Inc., Marina Street LLC, Axim Biotechnologies (the Netherland Company) and Sapphire Biotech, Inc. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated upon consolidation.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2022
GOING CONCERN
NOTE 4: GOING CONCERN	NOTE 4: GOING CONCERN The Company’s consolidated financial statements have been presented assuming that the Company will continue as a going concern. As shown in the consolidated financial statements, the Company has negative working capital of $2,914,013 and has an accumulated deficit of $63,226,126, has cash used in operating activities of continuing operations $1,728,821. The Company extinguished its old debt and entered in debt exchange agreement. On April 16, 2018, the Company entered into a Stock Purchase Agreement and sold 1,945,000 shares of our common stock registered under the Registration Statement on Form S-3 declared effective by the Securities and Exchange Commission on September 14, 2017. On March 11, 2019 the company issued shares in accordance with an SPA dated August 1, 2018 which the amount reduced due to shareholder by $400,000. During the year ended December 31, 2021, the Company raised additional capital of $1,610,538 through Stock Purchase Agreements. For the nine months ended September 30, 2022 the company raised $1,507,419 thru its S-1 and various stock purchase agreements This capital provides funds for research, development, and ongoing operations. The Company intends to raise substantial additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. That will raise a doubt about the ability of the Company to continue as a going concern. The consolidated financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2022
SIGNIFICANT ACCOUNTING POLICIES
NOTE 5: SIGNIFICANT ACCOUNTING POLICIES	NOTE 5: SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates. Significant estimates are assumptions about collection of accounts receivable, useful life of intangible assets and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate and expected dividend rate. Operating lease We lease property under various operating leases which are disclosed on our Balance sheet in accordance with ASC 842 Risks and uncertainties The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows; ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Beginning in late 2019, the outbreak of a novel strain of virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, has evolved into a global pandemic. The extent of the impact of the coronavirus outbreak on the Company’s business will depend on certain developments, including the duration and spread of the outbreak and the extent and severity of the impact on the Company’s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. At this point, the extent to which the coronavirus outbreak may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations. There have been no material changes in the accounting policies from those disclosed in the financial statements and the related notes included in the Form 10-K. Cash equivalents The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. As of September 30, 2022, the Company had no cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company had no uninsured balances at September 30, 2022 and December 31, 2021. The Company has never experienced any losses related to these balances. Accounts Receivable It is the Company’s policy to review accounts receivable at least on a monthly basis for conductibility and follow up with customers accordingly. Covid19 has slowed collection as our customers are in a mandated pause. We do not have geographic concentration of customers. Concentrations At September 30, 2022 and December 31, 2021, there was no accounts receivable. For the year ended December 31, 2021, one customer accounted for 100% of total revenue. For the three and nine months ended September 30, 2022 one customer accounted for 100% of sales. Property and equipment Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using straight-line method over the estimated useful life. New assets and expenditures that extend the useful life of property or equipment are capitalized and depreciated. Expenditures for ordinary repairs and maintenance are charged to operations as incurred. The Company’s property and equipment relating to continuing operations consisted of the following at September 30, 2022 and December 31, 2021, respectively, and none related to discontinued operations. September 30, 2022 December 31, 2021 Equipment of continuing operations $ 183,992 $ 175,283 Less: accumulated depreciation 81,923 58,473 $ 102,069 $ 116,810 Depreciation expense was $8,133 and $6,935 for the three months ended September 30, 2022 and 2021, respectively. Depreciation expense was $23,451 and $20,119 for the nine months ended September 30, 2022 and 2021, respectively. Intangible Assets Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. We conduct an impairment analysis for goodwill annually in the fourth quarter or more frequently if indicators of impairment exist or if a decision is made to sell or exit a business. Significant judgments are involved in determining if an indicator of impairment has occurred. Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others. The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill. We first may assess qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test included in U.S. GAAP. To the extent our assessment identifies adverse conditions, or if we elect to bypass the qualitative assessment, goodwill is tested using a quantitative impairment test. Impairment of Indefinite-Lived Intangible Assets For indefinite-lived intangible assets such as in-process research and development (IPRD), we conduct an impairment analysis annually in the fourth quarter or more frequently if indicators of impairment exist. We first perform a qualitative assessment to determine if it is more likely than not that the carrying amount of each of the in-process research and development assets exceeds its fair value. The qualitative assessment requires the consideration of factors such as recent market transactions, macroeconomic conditions, and changes in projected future cash flows. If we determine it is more likely than not that the fair value is less than its carrying amount of the in-process research and development assets, a quantitative assessment is performed. The quantitative assessment compares the fair value of the in-process research and development assets to its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized for the excess. We elected to perform a quantitative assessment of indefinite-lived intangible assets and determined that the fair value of the goodwill and IPRD related to the Sapphire acquisition was less than its carrying amount and that in-process research and development were fully impaired The Company’s intangible assets relating to continuing operations and discontinued operations consisted of the following at September 30, 2022 and December 31, 2021, respectively September 30, December 31, 2022 2021 Patents $ 250,000 $ 250,000 Licenses 4,270,000 4,270,000 4,520,000 4,520,000 Less: accumulated amortization 431,960 136,127 $ 4,088,040 $ 4,383,873 Estimated aggregate amortization expense for each of the five succeeding years ending December 31 is as follows: 2022 2023 2024 2025 2026 and thereafter Amortization expense $ 98,656 $ 394,450 $ 394,450 $ 394,450 $ 2,806,034 Amortization expense recorded for the three months ended September 30, 2022 and 2021 was $98,612 and $692,858; respectively. Amortization expense recorded for the nine months ended September 30, 2022 and 2021 was $295,835 and $1,333,954 respectively. Goodwill and Intangible assets were impaired resulting in a net impairment loss in 2021 of $5,966,452, resulting from an FDA decision not to approve our COVID test. This impairment was not recorded until December 31, 2021 Revenue Recognition The Company follows the guidance contained in Topic 606 (FASB ASC 606). The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods of services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. All revenue was from operations that were divested. Revenues are recognized when title for goods is transferred; non-refundable fees and proceeds from irrevocable agreements recognized when inflows or other enhancements of assets of the Company are received. Revenues from continuing operations recognized for three months ended September 30, 2022 and 2021 amounted to $1,314 and $8,127, respectively. Revenues from discontinued operations recognized for three months ended September 30, 2022 and 2021 amounted to $0 and $0, respectively. Revenues from continuing operations recognized for nine months ended September 30, 2022 and 2021 amounted to $1,314 and $55,651, respectively. Revenues from discontinued operations recognized for the nine months ended September 30, 2022 and 2021 amounted to $0 and $4,633, respectively. Collaboration Revenue Revenue recognition for collaboration agreements will require significant judgment. The Company’s assessments and estimates are based on contractual terms, historical experience and general industry practice. Revisions in these values or estimations have the effect of increasing or decreasing collaboration revenue in the period of revision. On August 21, 2020, the Company entered into a Distribution, License and Supply Agreement (“License Agreement”) with Empowered Diagnostics, LLC (“Empowered Diagnostics”). The License Agreement provides Empowered Diagnostics with a right to commercialize The Company’s products worldwide with the exception of Mexico. Under the License Agreement, the company is responsible for applying for and obtaining necessary regulatory approvals in the US and EU, as well as marketing, sales and distribution of the products. Empowered Diagnostics will pay a transfer price for all licensed products, and upon achievement of certain regulatory and sales milestones, the Company may receive payments from Empowered Diagnostics equal to 8% of the monthly gross revenue. Agreement continues until terminated by mutual consent or uncorrected breach. This agreement with Empowered Diagnostics was terminated in February 2022 The Company did not recognize any revenue from this agreement, Grant Income In 2021 the Company has received government grants to drive its research and development efforts. Through these government grants, the government has provided funding for the Company to perform research and development activities which will assist in developing its products. The Company believes the government entities funding these grants are interested in the Company advancing its underlying technologies through research activities and not providing incentives for hiring employees or building facilities that would suggest that the grant monies are not for specific research activities. In determining how to classify the monies received under government grants, the Company acknowledges that there is no specific guidance under US GAAP and that the FASB and AICPA have often drawn upon the guidance in IAS 20 for classification. In considering the alternatives provided by IAS 20 for the presentation of these grants in the Company’s financial statements, the Company believes that recognizing the government grant proceeds as a component of other revenue is a better reflection of the economics of the arrangements as the Company earns the funding through the performance of research and development which is not one of the Company’s primary business activities or central to its operations. The Company believes that presenting research and development funding from government grants, as other revenue provides consistency in our financial reporting. The Company also believes that this presentation clearly presents to users of its financial statements in one line the Company’s sources of funding from these grants. The Company notes that there are no contingencies associated with the receipt of or ability to retain the funds under the grant, other than undertaking and performing the related research and development activities. The Company recognizes funds received from contractual research and development services and from government grants as other revenue. These contracts and grants are not considered an ongoing major and central operation of the Company’s business. Our Income from Grants from Government for the three and nine months ended September 30, 2022 and 2021 was $0, $0 and $59,986, $279,981 respectively. Cost of Sales Cost of sales includes the purchase cost of products sold and all costs associated with getting the products to the customers including buying and transportation costs. Cost of sales all related to discontinued operations. Shipping Costs Shipping and handling costs billed to customers will be recorded in sales. Shipping costs incurred by the company are recorded in general and administrative expenses. Shipping costs all related to discontinued operations. Fair Value Measurements The Company applies the guidance that is codified under ASC 820-10 related to assets and liabilities recognized or disclosed in the financial statements at fair value on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The Company’s financial instruments are cash and cash equivalents, accounts receivable, accounts payable, notes payable, and long-term debt. The recorded values of cash and cash equivalents and accounts payable approximate their fair values based on their short-term nature. The recorded values of notes payable and long-term debt approximate their fair values, as interest approximates market rates. ASC 820-10 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820-10 requires valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows: Fair Value Hierarchy Inputs to Fair Value Methodology Level 1 Quoted prices in active markets for identical assets or liabilities Level 2 Quoted prices for similar assets or liabilities; quoted markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the financial instrument; inputs other than quoted prices that are observable for the asset or liability; or inputs that are derived principally from, or corroborated by, observable market information Level 3 Pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption is unobservable or when the estimation of fair value requires significant management judgment All items required to be recorded or measured on a recurring basis are based upon Level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement The Company recognizes its derivative liabilities as Level 3 and values its derivatives using the methods discussed below. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed are that of volatility and market price of the underlying common stock of the Company. The Company’s acquired goodwill with a carrying amount of $2,458,233 were written down to zero, resulting in an impairment charge of $2,458,233, which was included in earnings for the period ending September 30, 2020. In-process Research and Development with a carrying amount of $5,848,219 was written down to its implied fair value of zero, resulting in an impairment charge of $5,848,219, which was included in earnings for the period ending December 31, 2021. Items recorded or measured at fair value on a recurring basis in the accompanying condensed consolidated financial statements consisted of the following items as of September 30, 2022 Total Level 1 Level 2 Level 3 Derivative liabilities $ 1,995,618 $ - $ - $ 1,995,618 Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities.” Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of “Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability. Income Taxes The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including reversals of any existing taxable temporary differences, projected future taxable income, tax planning strategies, and the results of recent operations. If the Company determines that it would be able to realize a deferred tax asset in the future in excess of any recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25. No amounts were accrued for the payment of interest and penalties as of September 30, 2022 and December 31, 2021 respectively. The Company is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the Nine months ended September 30, 2022 and 2021 respectively. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “Cares Act”) was enacted. The CARES Act included loans and grants to certain businesses, and temporary amendments to the Internal Revenue Code which changed net loss carryforward and back provisions and the business interest expenses limitation. Under the CARES Act provisions, the most relevant income tax considerations to Oncocyte relate to the amounts received under the Paycheck Protection Program loan program and the possible forgiveness of those loans by the SBA. On December 21, 2020, the U.S. president has signed into law the “Consolidated Appropriations Act, 2021” which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans can deduct regular business expenses that are paid for with the loan proceeds for federal tax purposes. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company had $0 and $0 allowance for doubtful accounts at September 30, 2022 and 2021, respectively and had $0 accounts receivable at September 30, 2022 and $0 at December 31, 2021. Net Loss per Common Share Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-dilutive. There were common share equivalents 47,140,220 at September 30, 2022 and 30,119,877 at December 31, 2021. For the three and nine months ended September 30, 2022 and 2021 respectively these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share. Stock Based Compensation All stock-based payments to employees and to nonemployee directors for their services as directors, including any grants of restricted stock and stock options, are measured at fair value on the grant date and recognized in the statements of operations as compensation or other expense over the relevant service period. Stock-based payments to nonemployees are recognized as an expense over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable the measurement date is the date the award is issued. The Company accounts for stock options issued to non-employees based on the estimated fair value of the awards using the Black-Scholes option pricing model in accordance with ASC 505-50, Equity-Based Payment to Non-employees Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. For the three months and Nine months ended September 30, 2022 and 2021 the Company incurred research and development expenses of $29,722, $109,086 and $67,263, $216,282 respectively from continuing operations, respectively. For the three months and Nine months ended September 30, 2022 and 2021 the Company incurred research and development expenses of $0, $0 and $0, $0 from discontinued operations, respectively. The Company has entered into various agreements with CROs. The Company’s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. Recently Issued Accounting Standards Accounting Standards Implemented Since December 31, 2020 ASC Update 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update affect all entities that issue freestanding written call options that are classified in equity. Specifically, the amendments affect those entities when a freestanding equity-classified written call option is mod

PREPAID EXPENSES

PREPAID EXPENSES	9 Months Ended
	Sep. 30, 2022
PREPAID EXPENSES
NOTE 6: PREPAID EXPENSES	NOTE 6: PREPAID EXPENSES Prepaid expenses consist of the following as of September 30, 2022 and December 31, 2021 respectively: September 30, December 31, 2022 2021 Prepaid insurance $ 65,390 $ 59,116 Prepaid services - 104,445 $ 65,390 $ 163,561 For the three months ended September 30, 2022 and 2021 the Company recognized amortization of prepaid expense and prepaid insurance of $22,121 and $105,353 respectively. For the nine months ended September 30, 2022 and 2021 the Company recognized amortization of prepaid expense and prepaid insurance of $187,887 and $216,158 respectively.

PROMISSORY NOTE

PROMISSORY NOTE	9 Months Ended
	Sep. 30, 2022
PROMISSORY NOTE
NOTE 7: PROMISSORY NOTE	NOTE 7: PROMISSORY NOTE On December 31, 2019, Sapphire Biotech, Inc. had entered into a Debt Exchange Agreement whereas the Company assumed three (3) loans totaling $128,375 of Debt owned by Sapphire Diagnostics, LLC which had an interest rate of 6% per annum. In the same Debt Exchange Agreement, the Company assumed four (4) additional loans made to Sapphire in 2019, which had an interest rate of 6% per annum. All seven (7) loans totaling $310,000, plus the aggregate interest accrued thereon of $14,218 making the face value of the new note $324,218. As of September 30, 2022 and December 31, 2021 respectively, the principal and accrued interest balances were $-0- and $363,178 respectively. The note was refinanced January 27, 2022. With an effective date of April 1 2022. The Note is convertible into Axim common shares at a strike price of $0.1075 per share. The interest rate is 3% compounded monthly. The note is due January 27, 2032. This note now shows as a long term convertible note payable (see Note 11). On July 29, 2021, the Company recorded a $210,000 note payable in conjunction with the acquisition of patents from Advanced Tear Diagnostics LLC. The note balance as of December 31, 2021 is $90,000 with accrued interest of $1,515. The note was paid off February 2022 and has a zero balance as of September 30, 2022

OTHER COMMITMENTS

OTHER COMMITMENTS	9 Months Ended
	Sep. 30, 2022
OTHER COMMITMENTS
NOTE 8: OTHER COMMITMENTS	NOTE 8: OTHER COMMITMENTS Under an agreement Mr. Changoer received on March 20, 2018 the Company issued 50,000 restrictive shares of its common stock and recorded $235,000 of compensation expenses in the accompanying consolidated financial statements to account for the issuance of the incentive shares. As of September 30, 2022 and December 31, 2021 respectively, the total outstanding balance was $0 and $20,000 respectively for consulting fees to Mr. Changoer included in accounts payable. On September 25, 2018, the Company amended Independent Director Compensation agreement. Under the agreement in lieu of the share compensation due to independent director of the Company for his annual service ending May 23, Dr. Philip A. Van Damme shall receive cash compensation of $20,000. Started from August 1, 2019 the company has been paying monthly clinical trial fee of $5,000. As of September 30, 2022 and December 31, 2021 respectively, the total outstanding balance was $-0- and $0, respectively included in accounts payable. Effective January 1, 2019 the company entered into a thirty-months consulting agreement with the chairman of the board which pays a monthly consulting fee of $20,000. The company has also been paying a monthly bonus fee of 15,000; this additional fee is on a month-to-month basis at the discretion of management. As of September 30, 2022 and December 31, 2021 respectively, the total outstanding balance was $0 and $40,000 respectively for consulting fees included in accounts payable. On May 6, 2020 (the “Effective Date”), AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), entered into an Agreement (the “Separation Agreement”) by and among the Company, CanChew License Company (“CanCo”), CanChew Biotechnologies, LLC (“CanChew”), Medical Marijuana, Inc., Dr. George A. Anastassov (“Dr. Anastassov”), Dr. Philip A. Van Damme (“Dr. Van Damme”), Lekhram Changoer (“Mr. Changoer”), Sanammad Foundation, Netherlands and Sanammad Foundation, US (collectively, the “Sanammad Parties”), pursuant to which, among other matters as described herein, Drs. Anastassov and Van Damme and Mr. Changoer resigned as members of the Company’s Board of Directors. Pursuant to the Separation Agreement, the Company transferred and assigned to an entity designated by Dr. Anastassov all of the Company’s cannabis-related intellectual property other than the inventions and discoveries described in that certain cannabis-related patent application filed by the Company’s wholly-owned subsidiary, Sapphire Biotech, Inc. (water-soluble cannabinoid molecules). The Company also transferred 100% of its interest in CanCo and CanChew to an entity designated by Dr. Anastassov. In consideration for the transfers set forth above, any and all indebtedness owed by the Company to CanChew, totaling approximately $2.61 million, was satisfied and paid in its entirety. In addition, in consideration for the payment by the Company of $65,000, the Company purchased 100% of the issued and outstanding 500,000 shares of Series B Preferred Stock held by the Sanammad Parties. Such shares shall be retired to treasury of the Company. The Sanammad Parties also agreed to forfeit and assign back to treasury, for no consideration, a total of 18,570,356 shares of the Company’s common stock. In addition, each of Drs. Anastassov and Van Damme and Mr. Changoer have agreed to subject the shares of the Company’s common stock held by each of them to lock-up and leak-out restrictions, as follows: they shall not sell shares for a period of 12 months following the Effective Date and, thereafter, subject to a daily volume limitation of 5%, on an aggregate basis among them. Further, the Company terminated the Consulting Agreement of Dr. Anastassov and the Employment Agreements for each of Dr. Van Damme and Mr. Changoer. In connection with the termination of Dr. Anastassov’s Consulting Agreement, the Company agreed to pay severance in the amount of $35,000 for March 2020 and $20,000 per month thereafter through July 2021 (the termination date contemplated by the Consulting Agreement). Commencing for the April 2020, the Company may, in its sole discretion, pay the $20,000 severance obligation by the issuance of shares of the Company’s common stock registered pursuant to the Registration Statement on Form S-8 filed with the Commission on May 29, 2015 (“S-8 Shares”). If the gross cash proceeds from the sale of any S-8 Shares issued in lieu of cash severance is less than $20,000, as determined 20 days after issuance of such S-8 Shares, then the Company has agreed to issue additional shares that would serve to “true-up” the value of the shares to the $20,000 monthly severance obligation; provided, however, that if 30 days after the date the severance payment is due the gross proceeds from the sale of S-8 Shares is less than $20,000, the Company must pay the shortfall in cash. In addition, for each month that Dr. Anastassov is entitled to receive severance, he shall receive S-8 Shares in an amount equal to the lesser of (a) 150,000 S-8 Shares, or (b) S-8 Shares valued at $15,000 based upon the closing price of the Company’s common stock as of the due date of the severance payment obligation. In connection with the termination of the Employment Agreements of Dr. Van Damme and Mr. Changoer, Mr. Changoer’s severance payments shall be $20,000 per month for 12 months, commencing April 2020 (paid in arrears) and Dr. Van Damme’s severance payments shall be $5,000 per month for 12 months, similarly commencing April 2020 and paid in arrears. The Company has the right to pay each of Dr. Van Damme’s and Mr. Changoer’s monthly severance payments in S-8 shares in lieu of cash subject to the same terms and restrictions (including true-up terms) as set forth above for Dr. Anastassov. As of September 30, 2022, the accrued severance payment was $0 to Dr. Anastassov, 0 to Mr. Changoer. The Company retains the right to prepay the severance obligations to Drs. Anastassov and Mr. Changoer, without penalty. No claims were alleged by the Company against any party, and no claims were alleged against the Company. However, in connection with the transactions described above, the parties entered into a general mutual release of all claims.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2022
RELATED PARTY TRANSACTIONS
NOTE 9: RELATED PARTY TRANSACTIONS	NOTE 9: RELATED PARTY TRANSACTIONS Related Party The Company has an employment agreement with Catalina Valencia at a rate of $15,000 per month commencing March 17, 2020. The agreement can be terminated with 30 days’ notice by either party The company has a consulting agreement with Glycodots LLC whereby it will provide the services of Dr. Sergei A. Svarovsky at a rate of $15,000 per month commencing March 17, 2020. The agreement can be terminated with 30 days’ notice by either party.

DUE TO FIRST INSURANCE FUNDING

DUE TO FIRST INSURANCE FUNDING	9 Months Ended
	Sep. 30, 2022
DUE TO FIRST INSURANCE FUNDING
NOTE 10: DUE TO FIRST INSURANCE FUNDING	NOTE 10: DUE TO FIRST INSURANCE FUNDING On June 25, 2020, the Company renewed its D&O insurance policy with total premiums, taxes and fees for $93,357. A cash down payment of $18,671 was paid on July 6, 2020. Under the terms of the insurance financing, payments of $8,546, which include interest at the rate of 4.6% per annum, are due each month for nine months commencing on July 25, 2020. On June 25, 2021, the Company renewed its D&O insurance policy with total premiums, taxes and fees for $. A cash down payment of $24,273 was paid on July 7, 2021. Under the terms of the insurance financing, payments of $1,797, which include interest at the rate of 4.420% per annum, are due each month for nine months commencing on July 25, 2021. On June 25, 2022, the Company renewed its D&O insurance policy with total premiums, taxes and fees for $89,391. A cash down payment of $8,776 was paid on June 23, 2022. Under the terms of the insurance financing, payments of $8,957, which include interest at the rate of 4.920% per annum totaling 1628, are due each month for nine months commencing on July 25, 2022. The total outstanding due to First Insurance Funding as of September 30, 2022 and December 31, 2021 is $53,698 and $32,873, respectively.

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2022
CONVERTIBLE NOTES PAYABLE
NOTE 11: CONVERTIBLE NOTES PAYABLE	NOTE 11: CONVERTIBLE NOTES PAYABLE The following table summarizes convertible note payable of related party as of September 30, 2022 and December 31, 2021 respectively: September 30, December 31, 2022 2021 Convertible note payable, due on November 1, 2026, interest at 3.5% p.a. $ 4,000,000 $ 4,000,000 Accrued interest 261,537 299,037 Convertible note payable, net $ 4,261,537 $ 4,299,037 The interest on this note is payable bi-annually every May 1 and November 1. On May 1, 2019 the Company paid accrued interest of $60,278. In 2020 the Company was authorized to apply the accounts receivable of $75,074 due from Kannaway towards its accrued interest. On May 1, 2020, the Company agreed to modify its existing convertible note with a principal balance of $4 million, 3.5% interest rate convertible note with the current holder of that note. There were two changes to the existing agreement – (a) the conversion price was reduced from the $1.50 conversion price in the original Note to $0.25 cents in the modified Note and (b) the term of the note was extended from the original maturity date of November 1, 2021, to November 1, 2026. The Company’s stock closed trading on the day of the modification at $0.13 per share. The amendment of this convertible Note was also evaluated under ASC Topic 470-50-40, ”Debt Modifications and Extinguishments.” Based on the guidance, the instruments were determined to be substantially different due to the change in the conversion price being substantial, and debt extinguishment accounting was applied. The fair value of the modified convertible note was not different than the carrying value of the original note as such no extinguishment loss was recorded, The Note prior to the amendment of approximately $4 million, and the fair value of the Note and embedded derivatives after the amendment of approximately $4 million. There were no unamortized debt issuance costs and the debt discount associated with the original 2018 Note. For the three months ended September 30, 2022 and 2021, interest expense was $35,000 and $35,000, respectively. For the nine months ended September 30, 2022 and 2021, interest expense was $105,000 and $105,000, respectively. As of September 30, 2022 and December 31, 2021, the balance of secured convertible note was $4,261,537 and $4,299,037 which included $261,537 and $299,037 accrued interest, respectively. The following table summarizes convertible note payable as of September 30, 2022 and December 31, 2021 respectively: September 30, December 31, 2022 2021 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. $ 484,478 $ 484,478 Convertible Note payable, due on October 1, 2022, interest at 6% p.a. - 1,110,000 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. 500,000 500,000 Convertible note payable, due on February 10, 2032, interest at 3.0% p. a. 1,150,000 - Convertible note payable, due on December 31, 2034, interest at 3% p.a. 190,000 190,000 Convertible Note payable due January 27, 2032 interest at 3% p.a. 367,931 Accrued interest (The accrued interest and principal are both included in the captions titled “convertible note payable” in the balance sheet) 252,820 209,685 Total 2,945,229 2,494,163 Less: unamortized debt discount/finance premium costs (1,629,876 ) (605,639 ) Convertible note payable, net $ 1,315,353 $ 1,888,524 On September 16, 2016, we entered into a convertible note purchase agreement (the “Convertible Note Purchase Agreement” or “Agreement”) with a third-party investor. Under the terms of the Convertible Note Purchase Agreement the investor may acquire up to $5,000,000 of convertible notes from the Company. With various closings, under terms acceptable to the Company and the investor as of the time of each closing. Pursuant to the Agreement, on September 16, 2016 the investor provided the Company with $850,000 secured convertible note financing pursuant to four (4) Secured Convertible Promissory Notes (the “Notes”). Each of the Notes matures on October 1, 2029, and pay 3.5% compounded interest paid bi-annually. The Note are secured by the assets of the Company, may not be pre-paid without the consent of the holder, and are convertible at the option of the holder into shares of the Company common stock at a conversion price equal to $0.2201 per share. As of September 30, 2022 and December 31, 2021 respectively, the balance of secured convertible notes was $586,611 and $573,612, which included $102,133 and $89,134 accrued interest, respectively. On October 20, 2016 a third-party investor provided the Company with $1,000,000 secured convertible note financing pursuant to three (3) Secured Convertible Promissory Notes (the “Notes”). Each of the Notes mature on October 1, 2029 and pay 3.5% compounded interest paid bi-annually. The Notes are secured by the assets of the Company, may not be pre-paid without the consent of the holder, and are convertible at the option of the holder into shares of the Company’s common stock at a fixed conversion price equal of $0.2201 per share. The investor paid cash of $500,000 for one of the Notes and issued to the Company two (2) secured promissory notes of $250,000 each for two (2) Convertible Notes of $250,000 each. The two secured promissory notes issued by the investor (totaling $500,000) as payment for two (2) secured Notes totaling $500,000 mature on February 1, 2017 ($250,000) and March 1, 2017 ($250,000), bear interest at the rate of 1% per annum, are full recourse and additionally secured by 10,486,303 shares of Medical Marijuana, Inc. (Pink Sheets symbol: MJNA) and were valued at $858,828 based upon the closing price of MJNA on October 20, 2016. A debt discount was recorded related to beneficial conversion feature inn connection with this convertible note of $499,318, related to the beneficial conversion feature of the note to be amortized over the life of the note or until the note is converted or repaid. As of September 30, 2022 and December 31, 2021 respectively, this note has not been converted and the balance of secured convertible notes was $605,630 and $592,215, which included $105,630 and $92,215 accrued interest, respectively. On June 7, 2021 the Company converted $500,000 of the Convertible Note with TL-66-LLC along with the accrued interest of $82,707 into 2,647,464 shares of the Company’s common stock at $0.2201 per share which resulted in a loss on extinguishment of debt of $1,535,264. On December 31, 2019, Sapphire Biotech, Inc. entered into a Convertible Note Purchase Agreement whereas the Company issued a convertible note with a face value of $190,000 with a compounding interest rate of 3% per annum, the interest shall be payable annually beginning on December 31, 2020 until the maturity date of December 31, 2034, at which time all principal and interest accrued thereon shall be due and payable. The Convertible Note is secured by substantially all the Company’s tangible and intangible assets. In addition, the Convertible Note includes various non-financial covenants including the Company may not enter into any agreement, arrangement or understanding of any kind that would result in a transaction, or series of transactions, that would result in the sale of 50% or more of the Company’s capital stock without the prior approval of the holder. Upon issuance, the Convertible Note was convertible into shares of the Company’s common stock at $1.90 per share. At December 31, 2019, the Company determined that the Convertible Note contained a beneficial conversion feature for which a full discount was recorded on the Convertible Note. The fair market value of the Company’s common stock was based upon the estimated per share acquisition price per the pending acquisition of the Company. The discount of $190,000 will be amortized using the effective interest method and will be fully amortized by December 31, 2034. On March 17, 2020 the Company entered into a Share Exchange Agreement (“Agreement”) with Sapphire Biotech, Inc., a Delaware corporation (“Sapphire”) and all of the Sapphire stockholders (collectively, the “Sapphire Stockholders”). Following the closing of the transaction, Sapphire will become a wholly owned subsidiary of AXIM. Under the terms of the Agreement, the Company intends to assume the convertible notes in the principal amounts of $190,000. After the acquisition, the Convertible Note was able to convert 6,000,000 shares of Axim’s common stock. Upon assumption of the note, the Company recorded a beneficial conversion feature of $190,000. As of September 30, 2022 and December 31, 2021, the balance of secured convertible note was $205,690 and $201,416, which included $15,690 and $11,416 accrued interest, respectively. On July 21, 2020 the Company entered into convertible note purchase agreement with Cross & Company, the Company owed to Cross & Company $609,835 of aggregated payments and desired to satisfy the amount due in full by issuing to Cross & Company a convertible promissory note. The convertible note matures on July 21, 2032 and incurred 3.5% compounded interest paid annually. The Note are secured by the assets of the Company, may not be pre-paid without the consent of the holder, and are convertible at the option of the holder into shares of the Company common stock at a conversion price equal to $0.37. Notwithstanding the foregoing, holder shall not be permitted to convert the note, or portion thereof, if such conversion would result in beneficial ownership by holder and its affiliates of more than 4.9% of the debtor’s outstanding common stock as of the date of conversion. The Company determined that that the conversion of the amounts due into a long-term convertible note resulted in a debt extinguishment due to the change in the fair values exceeding 10%. Accordingly, the loss of $823,497 was included in the statement of operations as loss on debt extinguishment. As of September 30, 2022 and December 31, 2021, the balance of secured convertible note was $0 and $0, which included $0 and $0 accrued interest, respectively. The note was converted to 1,725,439 shares which included accrued interest at time of conversion of $28,578 common stock on November 24, 2021 at which time the company recorded loss on conversion expense of $51,763. On September 27, 2021 the Company entered into convertible note purchase agreement with GS Capital LLC in the amount of $1,110,000. The note had an original issue discount of $100,000, bridge financing fees of $100,000 and legal costs of $30,000, which were amortized to financing cost on the issuance of note. It bears interest at a rate of 6% and matures September 29, 2022. The note is convertible to free trading shares six months after issuance at a conversion price of $0.25 per share subject to a 10 day look back period at time of conversion if the stock is trading at less than $0.25 for more than 5 days then the conversion price will be a 30 percent discount to the average of the two lowest closing prices within the 10 day look back period. On February 10, 2022, the Company paid in full the remaining balance due on that certain convertible note issued to GS Capital Partners, LLC, face value $1,110,000 (as amended, the “GS Note”). In connection with the repayment, the Company was required to pay accrued interest in the amount of $21,863, by issuing 173,390 restricted shares of the Company’s common stock pursuant to the formula set forth in the GS Note. The shares were issued February 22, 2022 and valued at the closing price on that date at $0.19 per shares which was valued at $32,944 for the accrued interest of $21,863 and the balance $11,081 was recorded as loss on conversion under loss on extinguishment of debt in statement of operation. Also the Company paid $133,200 as penalty for early repayment recorded under interest expenses in statement of operation. As of September 30, 2022 and December 31, 2021, the balance of this convertible note was $0 and $1,126,919, which included $0 and $16,919 accrued interest; respectively. On December 31, 2019, Sapphire Biotech, Inc. had entered into a Debt Exchange Agreement whereas the Company assumed three (3) loans totaling $128,375 of Debt owned by Sapphire Diagnostics, LLC which had an interest rate of 6% per annum. In the same Debt Exchange Agreement, the Company assumed four (4) additional loans made to Sapphire in 2019, which had an interest rate of 6% per annum. All seven (7) loans totaling $310,000, plus the aggregate interest accrued thereon of $14,218 making the face value of the new note $324,218. As of September 30, 2022 and December 31, 2021 respectively, the principal and accrued interest balances were $375,427 and $0 respectively. The note was refinanced January 27, 2022. With an effective date of April 1 2022. The Note is convertible into Axim common shares at a strike price of $0.1075 per share. The interest rate is 3% compounded monthly. The note is due January 27, 2032. As a result of the beneficial conversion the company recognized a loss of $154,292 during the period ended September 30, 2022. Debt Obligations Effective February 10, 2022, The Company issued the following debt obligations in exchange for cash. A portion of the funds received by the Company were used to pay off the GS Capital Partners, LLC note, as discussed below. Short Term Promissory Notes Effective February 10, 2022, the Company issued two short term notes, each having a face amount of $250,000, in exchange for a total of $500,000 in cash (the “Short Term Promissory Notes”). The Short Term Promissory Notes bear interest at the rate of 1.5% per annum and were due and payable on or before March 10, 2022, unless demand for payment is made prior to such date. Both the notes were paid in full in February 2022. Convertible Notes Effective February 10, 2022, the Company issued seven convertible notes to a series of investors having an aggregate face value of $1,325,000 in exchange for $1,325,000 in cash (the “Convertible Notes”). One of the Convertible Notes, face value $25,000, was purchased by a director of the Company. Each of the Convertible Notes is (i) unsecured; (ii) bears interest at a rate of 3% per annum; (iii) matures on February 10, 2032; and (iv) is convertible, in whole or in part, at any time by the holder, into restricted shares of the Company’s common stock at a conversion price equal to the lesser of $0.08125 or 70% of the average of the two lowest closing prices of the Company’s common stock in the ten trading days preceding any particular conversion, provided, the holder is prohibited from converting the convertible note, or portion thereof, if such conversion would result in beneficial ownership by the holder and its affiliates of more than 4.999% of Company’s issued and outstanding common stock as of the date of the conversion. A debt discount was recorded related to beneficial conversion feature in connection with this convertible note of $1,325,000, which to be amortized over the life of the note or until the note is converted or repaid. During the third quarter 2022, $175,000 of the note and accrued interest of $2,840 was retired and converted to 5,665,636 common shares valued at $349,535 and a loss of $171,695 was recorded on conversion. Further the unamortized portion of debt discount of $167,571 and derivative liabilities balance of $227,459 on these notes were also transferred to loss on settlement account as gain and the company recorded a total net loss on conversion of debt of $111,807 on this transaction as loss on extinguishment of debt under statement of operation. During the three months ended September 30, 2022 and 2021 the Company amortized the debt discount on all the notes of $46,441 and $17,456, respectively. During the nine months ended September 30, 2022 and 2021 the Company amortized the debt discount on all the notes of $132,521 and $220,578 respectively. As of September 30, 2022 and December 31, 2021, unamortized debt discount was $1,629,876 and $605,639, respectively.

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES	9 Months Ended
	Sep. 30, 2022
DERIVATIVE LIABILITIES
NOTE 12: DERIVATIVE LIABILITIES	NOTE 12: DERIVATIVE LIABILITIES Upon the issuance of certain convertible note payable having a variable conversion rate, the Company determined that the features associated with the embedded conversion option embedded in the debt, should be accounted for at fair value, as a derivative liability. On February 10, 2022 i.e. on the date of issuance of derivative instrument, the Company estimated the fair value of the embedded derivatives of $2,641,846 using the Black-Scholes Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 163.09%, (3) risk-free interest rate of 2.03%, and (4) expected life of 10 years. The value of notes $1,325,000 was debited to beneficial conversion feature and the balance $1,316,846 was recorded as non-cash interest expenses under interest expenses in statement of operation. On September 30, 2022, the Company estimated the fair value of the embedded derivatives of $1,995,618 using the Black-Scholes Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 162.72%, (3) risk-free interest rate of 2.32%, and (4) expected life of 9.86 years. The change of $418,769 was recorded as gain on change in fair value of derivative liabilities for the nine months ended September 30, 2022. The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities for the nine months ended September 30, 2022: Balance, December 31, 2021 $ - Issuance of convertible note payable 2,641,846 Derivative liabilities on settlement of note transferred to gain on settlement (227,459 ) Mark to market (418,769 ) Balance, September 30, 2022 $ 1,995,618

STOCK INCENTIVE PLAN

STOCK INCENTIVE PLAN	9 Months Ended
	Sep. 30, 2022
STOCK INCENTIVE PLAN
NOTE 13: STOCK INCENTIVE PLAN	NOTE 13: STOCK INCENTIVE PLAN On May 29, 2015, the Company adopted its 2015 Stock Incentive Plan. Under the Plan the Company may issue up to 10,000,000 S-8 shares to officers, employees, directors or consultants for services rendered to the Company or its affiliates or to incentivize such parties to continue to render services. S-8 shares are registered immediately upon the filing of the Plan and are unrestricted shares that are free-trading upon issuance. On May 20, 2021 the board consent increased the issue up to 20,000,000 shares. As of September 30, 2022 and December 31, 2021 respectively, there were 9,635,350 and 9,806,000 shares available for issuance under the Plan. On August 2, 2021, Bijan Pedram the Senior Scientific of Sapphire Biotechnology was granted the options to purchase 0.1 million shares of Axim common stock under the plan at the purchase price of $0.67 per share. 25% of the Option shares will be vested upon the one anniversary of the vesting commencement day and the balance of the option shares will be vested of thirty-six (36) successive equal monthly in the first anniversary of the vesting commencement day. On August 17, 2021, Jeff Busby the Senior Vice president of Sales of Axim Biotechnology was granted the options to purchase 1 million of shares of Axim common stock under the plan at the purchase price of $0.60 per share. 25% of the Option shares will be vested upon the one anniversary of the vesting commencement day, 25% of the Option shares will be vested upon the two anniversaries of the vesting commencement day, 25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day. On September 1, 2021, Laura M. Periman Medical advisory board member of Axim Biotechnology was granted the options to purchase 0.1 million of shares of Axim common stock under the plan at the purchase price of $0.64 per share. 50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day. On September 4, 2021, Kelly K. Nichols Medical advisory Board member of Axim Biotechnology was granted the options to purchase 0.1 million of shares of Axim common stock under the plan at the purchase price of $0.62 per share. 50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day. On September 8, 2021, Joseph Tauber the Ophthalmic Chief Medical Officer (CMO) of Axim Biotechnology was granted the options to purchase 1 million of shares of Axim common stock under the plan at the purchase price of $0.622 per share. 25% of the Option shares will be vested upon the one anniversary of the vesting commencement day, 25% of the Option shares will be vested upon the two anniversaries of the vesting commencement day, 25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day. On August 22, 2022, 13,500,000 options were issued with a strike price of $0.052; 5,750,000 vesting immediately and the balance vesting between six months and a year from issuance. For the three months ended September 30, 2022 and 2021 the Company recorded compensation expense of $517,180 and $761,810, respectively. For the nine months ended September 30, 2022 and 2021 the Company recorded compensation expense of $888,313 and $953,076, respectively

STOCKHOLDERS DEFICIT

STOCKHOLDERS DEFICIT	9 Months Ended
	Sep. 30, 2022
STOCKHOLDERS DEFICIT
NOTE 14: STOCKHOLDERS' DEFICIT	NOTE 14: STOCKHOLDERS’ DEFICIT Preferred Stock The Company has authorized 5,000,000 shares of preferred stock, with a par value of $0.0001 per share. Of the 5,000,000 authorized preferred shares, 4,000,000 are undesignated “blank check” preferred stock. The Company may issue such preferred shares and designate the rights, privileges and preferences of such shares at the time of designation and issuance. As of September 30, 2022, and 2021 there are -0- and -0- shares of undesignated preferred shares issued and outstanding, respectively. There are zero shares issued and outstanding of Series A and Series B Preferred stock as of September 30, 2022. Series C Convertible Preferred Stock On August 17, 2016 the Company designated up to 500,000 shares of a new Series C Convertible Preferred Stock (Series C Preferred Stock). The holders of the Series C Preferred are entitled to elect four members to the Company’s board of directors and are entitled to cast 100 votes per share on all other matters presented to the shareholders for a vote. Each share of Series C Convertible Preferred is convertible into one share of the Company’s common stock. The Series C Convertible Preferred designation contains a number of protective and restrictive covenants that restrict the Company from taking a number of actions without the prior approval of the holders of the Series C Preferred or the unanimous vote of all four Series C Directors. If at any time there are four Series C Directors, one such director must be independent as that term is defined in the Series C designation. Any challenge to the independence of a Series C Director is a right conferred only upon the holders of the Series B Convertible Preferred Stock and may only be made by the holders of the Series B Convertible Preferred Stock. On August 18, 2016 the Company issued all 500,000 shares of its newly designated Series C Preferred Stock to MJNA Investment Holdings, LLC in exchange for cash of $65,000. As the holders of the Series C Preferred Stock, MJNA Investment Holdings, LLC has designated Dr. Timothy R. Scott, John W. Huemoeller II, Robert Cunningham and Blake Schroeder as their four Series C Directors. On February 20, 2019, MJNA Investment Holdings LLC (“Seller”) sold its 500,000 shares of AXIM Biotechnologies, Inc.’s, a Nevada corporation (the “Company”) Series C Preferred Stock to Juniper & Ivy Corporation, a Nevada corporation (“Purchaser”) for a purchase price of $500,000 (the “Purchase Price”) pursuant to a Preferred Stock Purchase Agreement (the “Purchase Agreement”). Payment of the Purchase Price was made as follows (i) a $65,000 payment made by check payable to Seller, which Purchaser borrowed from an unrelated third-party and which has no recourse against the Series C Preferred Stock or assets of Purchaser (the “Loan”), and (ii) the issuance by Purchaser to Seller of a promissory note, face value, $435,000, which has no recourse against the Series C Preferred Stock or assets of Purchaser (the “Note”). The Company’s Chief Executive Officer John W. Huemoeller II is the President of Purchaser. Mr. Huemoeller provided a personal guaranty for the Loan and the Note. The holders of the Series C Preferred Stock are entitled to elect four members to the Company’s Board of Directors and are entitled to cast 100 votes per share on all other matters presented to the shareholders for a vote. As a result of this transaction, a change in control has occurred. Common Stock The Company has authorized 300,000,000 shares of common stock, with a par value of $0.0001 per share. As of September 30, 2022 and December 31, 2021, the Company had 185,441,917 and 138,099,981 shares of common stock issued and outstanding, respectively. 2022 Transactions: During January 2022, the Company issued 519,247 shares for cash of gross proceeds of $75,000 pursuant to various stock purchase agreements. The cash was received in the fourth quarter 2021 and first quarter 2022. The Company also issued warrants to purchase an aggregate of 519,247 shares of common stock at an average exercise price of $0.315 per share. The warrants are exercisable within a 3-year period from issuance. In January 2022, the Company issued 7,000,000 shares of its common stock pursuant to its asset acquisition of Advanced Tear Diagnostics which was under common stock to be issued. In January 2022, the Company issued 302,115 of its shares of common stock, valued at $100,000, in exchange for services which have been recorded as a prepaid expense. On January 11, 2022, the company issued 282,759 shares of common stock upon the exercise of 500,000 options at an exercise price of $0.126 a share. This exercise was performed on a cashless basis. In March 2022, the Company issued 624,290 of its shares of common stock pursuant to a stock purchase agreement for cash gross proceeds of $55,000. In March 2022, the Company issued 173,390 shares of its common stock, valued at $32,944, in settlement of interest due to prepayment of a note and the Company recognized a loss on conversion of $11,081 under loss on extinguishment of debt in statement of operation. In March 2022, the company issued 500,000 of its shares of common stock, valued at $79,500 in exchange for services related to the arrangement of meetings and conferences. The Company also issued 10,750,000 shares of its common stock January thru June of 2022 for cash of $881,255 pursuant to an equity purchase agreement, dated on May 14, 2021, which shares were registered pursuant to that S-1 Registration Statement filed by the Company with the SEC on May 14, 2021, and declared effective by the SEC on June 22, 2021. The Company issued 891,610 of its shares to settle the amounts owed to George Anastassov and Lekhram Changoer. The debt totaled $60,000 and the company recognized a loss on settlement of $4,196 The Company issued 3,544,247 of its shares in settlement of claims made by individuals pursuant to various stock Purchase agreements. The company recognized a current period loss of $226,171 as a result of this settlement. During the third quarter 2022 the company issued 2,227,638 shares pursuant to its S-1 for cash of $138,991 and a subscription receivable of $60,064. On July 14, 2022, the Company entered into the Equity Purchase Agreement with Cross & Company, pursuant to which we have the right to “put,” or sell, up to $30,000,000 worth of shares of our common stock to Cross. As provided in the Equity Purchase Agreement, we may require Cross to purchase shares of our common stock from time to time by delivering a put notice to Cross specifying the total number of shares to be purchased (such number of shares multiplied by the purchase price described below, the “Investment Amount”); provided there must be a minimum of ten trading days between delivery of each put notice. We may determine the Investment Amount, provided that such amount may not be more than 300% of the average daily trading volume in dollar amount for our common stock during the five trading days preceding the date on which we deliver the applicable put notice, unless waived by Cross in its sole discretion. Additionally, such amount may not be lower than $10,000 or higher than $250,000. Cross will have no obligation to purchase shares under the Equity Line to the extent that such purchase would cause Cross to own more than 4.99% of our issued and outstanding shares of common stock. The Company also issued 1,000,000 shares of its common stock January thru September of 2022 for cash of $60,064 pursuant to an equity purchase agreement, dated on July 14, 2022, which shares were registered pursuant to that S-1 Registration Statement filed by the Company with the SEC on July 25, 2022, and declared effective by the SEC on August 4, 2022. The subscription amount of $60,064 was received subsequent to September 30 2022. This was shown as subscription receivable on the equity statement. Also during the third quarter of 2022 the company issued 13,861,004 shares pursuant to various stock purchase agreements for cash of $350,000. The Company converted debt of $177,840 including accrued interest of $2,840 in exchange for 5,665,636 shares of its stock valued at $349,535 and as a result recognized a loss on extinguishment of $111,807, including cancellation of balance debt discount of $167,571 and a gain due to cancellation of derivative liabilities as of date of settlement of $227,459. 2021 Transactions: Common Stock On December 13, 2021 the company entered into an agreement where it will issue $100,000 of stock in exchange for services to be rendered under a consulting agreement, currently shown as stock to be issued. On November 7, 2021 the company issued 1,725,439 of its shares in settlement of a debt of 638,412 including accrued interest of $28,578. During the period between May 14, 2021 and December 31, 2021 the Company issued total 500,000 shares valued $129,274 pursuant to the Company’s Registration Statement on Form S-1. The Company received $129,274 in cash. On October 12, 2021 the Company issued 118,000 shares to GS capital valued at $57,466 pursuant to services rendered in obtaining financing. On October 18, 2021 the company issued 175,000 shares of its common stock valued at $52,500 pursuant to a stock purchase agreement. During the year ended December 31, 2021, the company issued 196,438 shares of common stock upon the exercise of 300,000 options at an exercise price of $0.126 a share. This exercise was performed on a cashless basis. On July 29, 2021 the Company issued 122,000 restricted shares of its common stock to third party valued at $50,000 pursuant to the stock purchase agreement. The cash was received in 2021. During August and September 2021 the Company issued 1,060,715 commons shares and warrants to purchase 1,060,715 shares of common stock at an exercise price of $0.60 for gross cash proceeds of $297,000 pursuant to various Warrant Stock purchase agreements. The cash was received in the third quarter ending 2021. Warrants are exercisable within a 3-year period from issuance. During July and September 2021 the company issued 1,415,554 restricted shares of its common stock valued at $1,111,900 to third parties for certain services, recorded as consulting fees. In September 2021 the company issued 262,400 restricted shares of its common stock valued at $129,724 pursuant to S-1 Agreement to third party for cash, recorded as subscription receivable. Pursuant to its purchase of Advanced Tear Diagnostics, LLC the company has recorded 7,000,000 shares of its common stock to be issued valued at $4,270,000. On May 14, 2021, The Company entered into the Equity Purchase Agreement with Cross, pursuant to which we have the right to “put,” or sell, up to $10,000,000 worth of shares of our common stock to Cross. As provided in the Equity Purchase Agreement, we may require Cross to purchase shares of our common stock from time to time by delivering a put notice to Cross specifying the total number of shares to be purchased (such number of shares multiplied by the purchase price described below, the “Investment Amount”); provided there must be a minimum of ten trading days between delivery of each put notice. We may determine the Investment Amount, provided that such amount may not be more than 500% of the average daily trading volume in dollar amount for our common stock during the five trading days preceding the date on which we deliver the applicable put notice, unless waived by Cross in its sole discretion. Additionally, such amount may not be lower than $10,000 or higher than $1,000,000. Cross will have no obligation to purchase shares under the Equity Line to the extent that such purchase would cause Cross to own more than 4.99% of our issued and outstanding shares of common stock. In June 2021 the company issued 500,000 restricted shares of its common stock valued at $332,500 pursuant to S-1 Agreement to third party recorded as subscription receivable. Actual proceeds were $228,812. The difference of $103,688 was adjusted to additional paid in capital and was calculated in accordance with the S-1 agreement. During April, May and June 2021 the company issued 2,647,464 restricted shares of its common stock valued at $2,117,971 pursuant to conversion of convertible note and accrued interest of $582,707 (Note 12) with a loss on extinguishment of debt $1,535,264. During April, May and June 2021 the Company issued 1,234,113 shares for cash of gross proceed of $402,500 pursuant to various Warrant Stock purchase agreements. The cash was received in the second quarter ending 2021. Out of these 519,828 shares of common stock valued at $152,500 was adjusted with common stock to be issued of prior period. The company also issued warrants to purchase 175,000 shares of common stock at an exercise price of $0.75 and 714,285 shares of common stock at an exercise price of $0.80. Warrants are exercisable within a 3 year period from issuance. During April, May and June 2021 the company issued 1,114,351 restricted shares of its common stock valued at $792,389 to third parties for certain services, recorded as consulting fees. During March 2021 the Company issued 1,712,500 shares for cash of gross $434,000 pursuant to various Stock purchase agreements. The cash was received in the first quarter ending 2021. The company also issued warrants to purchase 900,000 shares of common stock at an exercise price of $0.75. Warrants are exercisable within a 3 year period from issuance. Company paid finders fees of $20,000 in cash during this period for capital raise and will also issue shares equaling $16,000 in market value, which was issued during the year ended December 31, 2021. On March 18, 2021 the company issued 488,428 restricted shares of its common stock valued at $291,974 to third parties for certain services, recorded as consulting fees. Out of these 108,965 shares of common stock valued at $66,974 was adjusted with common stock to be issued of prior year.

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	9 Months Ended
	Sep. 30, 2022
STOCK OPTIONS AND WARRANTS
NOTE 15: STOCK OPTIONS AND WARRANTS	NOTE 15: STOCK OPTIONS AND WARRANTS Options to purchase common stock are granted at the discretion of the Board of Directors, a committee thereof or, subject to defined limitations, an executive officer of the Company to whom such authority has been delegated. Options granted to date generally have a contractual life of ten years. The stock option activity for three months ended September 30, 2022 and year ended December 31, 2021 respectively is as follows: Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2020 10,300,000 $ 0.36 Granted 2,960,715 0.60 Exercised (300,000 ) 0.35 Expired or canceled (2,000,000 ) 0.75 Outstanding at December 31, 2021 10,960,715 $ 0.37 Granted 13,500,000 0.052 Exercised (500,000 ) 0.37 Balance September 30, 2022 23,960,715 $ 0.19 The following table summarizes the changes in options outstanding, option exercisability and the related prices for the shares of the Company’s common stock issued to employees and consultants under a stock option plan at September 30, 2022: As of September 30, 2022 Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.19 23,960,715 9.0 $ 0.19 17,141,095 $ 0.19 As of December 31, 2021 Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.36 10,960,715 8.5 $ 0.37 8,094,046 $ 0.37 The Company determined the value of share-based compensation for options vested using the Black-Scholes fair value option-pricing model with the following weighted average assumptions: September 30, December 31, 2022 2021 Expected life (years) 10 10 Risk-free interest rate (%) 3.03 1.74 Expected volatility (%) 229 190 Dividend yield (%) - - Weighted average fair value of shares at grant date $ 0.19 $ 1.74 For the three months ending September 30, 2022 the company issued 13,500,000 options with a value of $675,000. For the three and nine months ended September 30 2022 and 2021 the company recorded compensation expense of $517,180, $888,313 and $761,810, $953,076 respectively. Warrants The following table summarizes warrant activity during the year ended December 31, 2021 and the nine months ended September 30, 2022: Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2020 - $ - Granted 3,025,000 0.71 Forfeited/Cancelled - - Exercised - - Outstanding at December 31, 2021 3,025,000 $ 0.71 Granted 519,247 0.31 Exercised Outstanding at September 30, 2022 3,544,247 0.65 All outstanding warrants are exercisable at September 30, 2022 and there was no unrecognized stock-based compensation expense related to warrants.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	9 Months Ended
	Sep. 30, 2022
DISCONTINUED OPERATIONS
NOTE 16: DISCONTINUED OPERATIONS	NOTE 16: DISCONTINUED OPERATIONS During May 2020 the Company decided to discontinue most of its operating activities pursuant to the Separation Agreement entered into by and among the Company, CanChew License Company (“CanCo”), CanChew Biotechnologies, LLC (“CanChew”), Medical Marijuana, Inc., Dr. George A. Anastassov (“Dr. Anastassov”), Dr. Philip A. Van Damme (“Dr. Van Damme”), Lekhram Changoer (“Mr. Changoer”), Sanammad Foundation, Netherlands and Sanammad Foundation, US (collectively, the “Sanammad Parties”). (see Note 1). Pursuant to the terms of the Purchase Agreement dated as of May 6, 2020, Sanammad Parties agreed to acquire from the Company substantially all of its assets and its wholly-owned subsidiaries and to assume certain liabilities and its wholly-owned subsidiaries. Sanammad Parties agreed to pay a purchase price of $2,609,100 reflected in amount due Canchew were deemed paid in full. The sale, which was completed on May 6, 2020, did not include the Company’s cash and certain other excluded assets and liabilities. The results of operations associated with the assets sold have been reclassified into discontinued operations for periods prior to the completion of the transaction. As of September 30, 2022 and December 31, 2021 respectively, the Company has nil asset and liabilities of the discontinued operations in the unaudited condensed consolidated balance sheet in accordance with the provision of ASC 205-20. Loss from Discontinued Operations In 2020, the sale of the majority of the assets and liabilities related to the Sanammad parties represents a strategic shift in the Company’s business. For this reason, the results of operations related to the assets and liabilities held for sale for all periods are classified as discontinued operations. The following is a summary of the results of operations related to the assets and liabilities held for sale (discontinued operations) for the nine months ended September 30, 2022 and 2021 respectively: September 30, 2022 September 30, 2021 Net sales $ - $ - Total expenses $ - $ (4,633 ) Gain from sale of asset and liability $ - $ - Other (loss) income $ - $ - (Loss) income from discontinued operations $ - $ (4,633 ) The following is a summary of net cash provided by or used in operating activities, investing activities and financing activities for the assets and liabilities held for sale (discontinued operations) for the nine months ended September 30, 2022 and 2021 respectively: September 30, 2022 September 30 2021 Net (loss) income from discontinued operations $ - $ (4,633 ) Adjustment of non-cash activities - - Decrease in accounts receivable - - Increase in inventory - - Increase in accounts payable and accrued expenses - - Net cash provided by (used in) operating activities $ - $ (4,633 ) Net cash provided by (used in) investing activities $ - $ - Net cash provided by (used in) financing activities $ - $ - As of September 30, 2022 and December 31, 2021 respectively, the Company has nil asset and liabilities of the discontinued operations in the unaudited condensed consolidated balance sheet in accordance with the provision of ASC 205-20.

COMMITMENT AND CONTINGENCIES

COMMITMENT AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
OTHER COMMITMENTS
NOTE 17: COMMITMENT AND CONTINGENCIES	NOTE 17: COMMITMENT AND CONTINGENCIES On January 2, 2019 the Company entered into the term of Executive’s employment agreement, at a base salary of $10,000 per month with John W. Huemoeller II to serve as its Chief Executive Officer. The Company and Executive acknowledge and agree that Executive’s employment hereunder shall at all times be “at will,” which means that either Executive may resign at any time for any reason or for no reason, and that the Company may terminate Executive’s employment at any time for any reason or for no reason, in either case, subject to the applicable provisions of this Agreement. In further consideration for Executive’s services and subject to the approval of the Board, Executive will be granted an option to purchase 2,000,000 shares of the Company’s common stock (the “Option Shares”). The option will be subject to the terms and conditions applicable to stock options granted under the Company’s 2015 Stock Incentive Plan, as amended from time to time (the “Plan”), and as described in the Plan and the stock option agreement, which Executive will be required to sign. 50% of the Option Shares shall vest on the date of grant and the remaining 50% of the Option Shares shall vest on the 12- month anniversary of the grant date, subject to Executive’s continued employment by the Company. The exercise price per share will be equal to the fair market value per share on the date of grant, as determined by the last closing price of the Company’s common stock the day prior to grant. Beginning in October 2019, the board decided to increase CEO base salary to $35,000 per month. On April 24, 2017 the company entered into an employment agreement with Robert Malasek, its Chief Financial Officer and Secretary. The agreement does not have a set term and may be terminated at any time by the Company or Mr. Malasek with proper notice. The shares were issued in the 1 st Industry Sponsored Research Agreement— Sapphire entered into the Industry Sponsored Research Agreement (“SRA”) effective February 7, 2020 to test and confirm the inhibitory activity of SBI-183 (exclusively licensed on January 13, 2020) and SBI-183 analogs, including those synthesized by the Company. The testing will include cell-based in vitro assays, NMR binding studies and testing to determine if SBI-183 enhances the activity of cytotoxic drugs in vitro. Animal studies will also be conducted under the SRA. Specifically, SBI-183 analogs will be evaluated in a mouse model of triple negative breast cancer using human tumor xenografts. The work will be performed over a period of one year with the total cost of the SRA totaling $150,468 paid prior to acquisition. For the year December 31, 2021, the Company recorded research and development expenses of $284,869. On August 5, 2020 Sapphire was awarded a $395,880 phase I Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI). The grant will support continued development of novel small molecules that inhibit the enzymatic activity of Quiescin Sulfhydryl Oxidase I (QSOX1) based on a lead compound. QSOX1 is a tumor-derived enzyme that is important for cancer growth, invasion and metastasis. Sapphire is conducting this research with technology it has exclusively licensed from Skysong Innovations, LLC, the intellectual property management company for Arizona State University. Sapphire will subcontract tumor biology work for evaluating analog inhibitors for QSOX1 to Dr. Doug Lake’s laboratory at Arizona State University and Mayo Clinic Arizona. Grant income received for the years ended 2021 was $279,981. There was nil in 2022. On August 25, 2020 we signed an exclusive licensing, manufacturing and distribution agreement with Empowered Diagnostics LLC to execute the high-volume production of our rapid point-of-care diagnostic test. AXIM and Empowered have completed the technology transfer and Empowered Diagnostics has built out their production facility to be able to manufacture millions of our neutralizing antibody tests for COVID-19 per month. In exchange for this license Empowered will pay Axim a royalty on net sales on all licensed products sold by Empowered covered by this license which global with the exception of Mexico. This agreement was cancelled in February, 2022. On September 15, 2022 the company entered into a license and distribution agreement for its Lactoferrin dry eye test, Ige allergy test for allergic conjunctivitis and quantitative MMp-9 test to identify ocular surface inflammation. Axim was paid an initial license fee of $150,000 and has the right to cancel the agreement if minimum sales targets are not reached. This amount was recorded as deferred revenue and amortized over 5 years beginning September 15, 2022. The licensee is Versea Ophthalmics, LLC, A Delaware Limited Liability Company. The agreement will provide Verséa with the exclusive commercial right to AXIM’s proprietary portfolio of point-of-care (POC) lab testing readers and three key biomarker diagnostic tests designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient Dry Eye Disease and non-specific allergic conjunctivitis. The three AXIM’s key biomarker tests – the Ocular Immunoglobulin E (IgE) test, the Lactoferrin test, and the future MMP-9 test – require the collection of 0.5 microliters in tears and provide quantitative results in under 10 minutes, an industry-leading return time. Verséa plans to launch IgE and Lactoferrin tests at the upcoming 2022 American Academy of Ophthalmology (AAO) and American Academy of Optometry (AAOPT) conferences. The MMP-9 test is anticipated to follow in the next 18-24 months. In recent months, AXIM has been preparing for the scaling of production of its tests in anticipation of an agreement such as the one reached with Verséa and is now prepared to support new orders associated with the agreement and subsequent launch. Operating Lease Lease Agreement—On March 3, 2020, Sapphire entered into a 3-year lease agreement (“Lease”) to relocate to a larger space within the same business park. The new space totals 1,908 square feet with monthly base rent in the 1st year $4,713, 2nd year $4,854 and 3rd year $5,000 at implicit interest rate of 6%. Upon commencement of the Lease on April 25, 2020, the previous lease will expire. Operating Leases - Right of Use Assets and Purchase Commitments Right of Use Assets We have operating leases for office space that expire through 2023. Below is a summary of our right of use assets and liabilities as of September 30, 2022. Right-of-use assets $ 34,374 Lease liability obligations, current $ 34,374 Lease liability obligations, noncurrent Total lease liability obligations $ 34,374 Weighted-average remaining lease term 0.58 years Weighted-average discount rate 6 % The following table summarizes the lease expense for the three and nine months ended September 30, 2022 and 2021 respectively: Three Months ended September 30, 2021 September 30, September 30, 2022 2021 Operating lease expense $ 15,000 * $ 14,421 Short-term lease expense 12,932 4,166 Total lease expense $ 27,932 $ 18,587 *We recorded $27,932 of operating lease expense this includes $15,644 of maintenance charges and month to month lease. Nine Months ended September 30, 2022 September 30, September 30, 2022 2021 Operating lease expense $44,416 ** $ 43,122 Short-term lease expense 45,292 11,545 Total lease expense $89,708 ** $ 54,667 **We recorded $89,708 of operating lease expense this includes $45,292 of maintenance and month to month lease charges. Approximate future minimum lease payments for our right of use assets over the remaining lease periods as of September 30, 2022, are as follows: 2022 $ 15,000 2023 20,000 Total minimum payments 35,000 Less: amount representing interest (626 ) Total $ 34,374 Litigation As of December 31, 2021, and this report issuing date, the Company is not a party to any pending material legal proceeding. To the knowledge of management, no federal, state or local governmental agency is presently contemplating any proceeding against the Company. To the knowledge of management, no director, executive officer or affiliate of the Company, any owner of record or beneficially of more than five percent of the Company’s Common Stock is a party adverse to the Company or has a material interest adverse to the Company in any proceeding.

NOTES RECEIVABLE

NOTES RECEIVABLE	9 Months Ended
	Sep. 30, 2022
NOTES RECEIVABLE
NOTE 18: NOTES RECEIVABLE	NOTE 18: NOTES RECEIVABLE Purchase of Promissory Note and Forbearance Agreement Effective May 4, 2020, the Company acquired from TL-66, a California limited liability company (“Seller”), a promissory note issued to Seller by Dr. Anastassov (“Maker”) dated December 1, 2017, with a face value of $350,000 and a remaining balance due of approximately $100,000 (the “Note”). The purchase price for the Note was $100,000 payable by the Company issuing Seller One Million (1,000,000) restricted shares of the Company’s Common Stock. Effective May 6, 2020, the Company and Maker entered into a Forbearance Agreement whereby the Company agreed to forbear from making any collection efforts on the Note for a period of 24 months so long as Maker has not breached the Separation Agreement. Following 24 months, if there has been no breach of the Separation Agreement by Maker, repayment of the Note, including all principal and unpaid interest, will be waived in full. As of May, 4, 2020 the carrying value of the note receivable was $102,567, the value of the common stock to be issued was $135,000, resulting in a loss of $32,433 accounted as loss on debt extinguishment related to discontinued operations. The balance of the Note Receivable as of September 30, 2022 and December 31, 2021 respectively is $0 and $102,567 excluding interest accrued thereon of $0 and $1,701, respectively. The repayment of the note including all principal and interest has been waived and the remaining balance was recorded as severance cost of $102,387 during the nine months ended September 30, 2022.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
SUBSEQUENT EVENTS
NOTE 18: SUBSEQUENT EVENTS	NOTE 19: SUBSEQUENT EVENTS Common Stock Issuances On October 27, 2022, Company issued 1,000,000 shares of its common pursuant to an equity purchase agreement, dated on July 14, 2022, which shares were registered pursuant to that S-1 Registration Statement filed by the Company with the SEC on July 25, 2022, and declared effective by the SEC on August 4, 2022. The subscription amount is not received as of date. Employees Termination On September 15, 2022, the Company entered into a License and Distribution Agreement with Versea Ophthalmics, LLC (“Agreement”). Due to the Agreement, the positions of: (i) National Sales Director; and (ii) Chief Medical Officer held by Jeff Busby and Dr. Joseph Tauber, respectively, were no longer necessary for Company operations and, therefore, eliminated.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2022
SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates. Significant estimates are assumptions about collection of accounts receivable, useful life of intangible assets and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate and expected dividend rate.
Operating Lease	We lease property under various operating leases which are disclosed on our Balance sheet in accordance with ASC 842
Risks and Uncertainties	The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows; ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Beginning in late 2019, the outbreak of a novel strain of virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, has evolved into a global pandemic. The extent of the impact of the coronavirus outbreak on the Company’s business will depend on certain developments, including the duration and spread of the outbreak and the extent and severity of the impact on the Company’s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. At this point, the extent to which the coronavirus outbreak may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations. There have been no material changes in the accounting policies from those disclosed in the financial statements and the related notes included in the Form 10-K.
Cash Equivalents	The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. As of September 30, 2022, the Company had no cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company had no uninsured balances at September 30, 2022 and December 31, 2021. The Company has never experienced any losses related to these balances.
Accounts Receivable	It is the Company’s policy to review accounts receivable at least on a monthly basis for conductibility and follow up with customers accordingly. Covid19 has slowed collection as our customers are in a mandated pause. We do not have geographic concentration of customers.
Concentrations	At September 30, 2022 and December 31, 2021, there was no accounts receivable. For the year ended December 31, 2021, one customer accounted for 100% of total revenue. For the three and nine months ended September 30, 2022 one customer accounted for 100% of sales.
Property and Equipment	Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using straight-line method over the estimated useful life. New assets and expenditures that extend the useful life of property or equipment are capitalized and depreciated. Expenditures for ordinary repairs and maintenance are charged to operations as incurred. The Company’s property and equipment relating to continuing operations consisted of the following at September 30, 2022 and December 31, 2021, respectively, and none related to discontinued operations. September 30, 2022 December 31, 2021 Equipment of continuing operations $ 183,992 $ 175,283 Less: accumulated depreciation 81,923 58,473 $ 102,069 $ 116,810 Depreciation expense was $8,133 and $6,935 for the three months ended September 30, 2022 and 2021, respectively. Depreciation expense was $23,451 and $20,119 for the nine months ended September 30, 2022 and 2021, respectively.
Intangible Assets	Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. We conduct an impairment analysis for goodwill annually in the fourth quarter or more frequently if indicators of impairment exist or if a decision is made to sell or exit a business. Significant judgments are involved in determining if an indicator of impairment has occurred. Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others. The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill. We first may assess qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test included in U.S. GAAP. To the extent our assessment identifies adverse conditions, or if we elect to bypass the qualitative assessment, goodwill is tested using a quantitative impairment test. Impairment of Indefinite-Lived Intangible Assets For indefinite-lived intangible assets such as in-process research and development (IPRD), we conduct an impairment analysis annually in the fourth quarter or more frequently if indicators of impairment exist. We first perform a qualitative assessment to determine if it is more likely than not that the carrying amount of each of the in-process research and development assets exceeds its fair value. The qualitative assessment requires the consideration of factors such as recent market transactions, macroeconomic conditions, and changes in projected future cash flows. If we determine it is more likely than not that the fair value is less than its carrying amount of the in-process research and development assets, a quantitative assessment is performed. The quantitative assessment compares the fair value of the in-process research and development assets to its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized for the excess. We elected to perform a quantitative assessment of indefinite-lived intangible assets and determined that the fair value of the goodwill and IPRD related to the Sapphire acquisition was less than its carrying amount and that in-process research and development were fully impaired The Company’s intangible assets relating to continuing operations and discontinued operations consisted of the following at September 30, 2022 and December 31, 2021, respectively September 30, December 31, 2022 2021 Patents $ 250,000 $ 250,000 Licenses 4,270,000 4,270,000 4,520,000 4,520,000 Less: accumulated amortization 431,960 136,127 $ 4,088,040 $ 4,383,873 Estimated aggregate amortization expense for each of the five succeeding years ending December 31 is as follows: 2022 2023 2024 2025 2026 and thereafter Amortization expense $ 98,656 $ 394,450 $ 394,450 $ 394,450 $ 2,806,034 Amortization expense recorded for the three months ended September 30, 2022 and 2021 was $98,612 and $692,858; respectively. Amortization expense recorded for the nine months ended September 30, 2022 and 2021 was $295,835 and $1,333,954 respectively. Goodwill and Intangible assets were impaired resulting in a net impairment loss in 2021 of $5,966,452, resulting from an FDA decision not to approve our COVID test. This impairment was not recorded until December 31, 2021
Revenue Recognition	The Company follows the guidance contained in Topic 606 (FASB ASC 606). The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods of services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. All revenue was from operations that were divested. Revenues are recognized when title for goods is transferred; non-refundable fees and proceeds from irrevocable agreements recognized when inflows or other enhancements of assets of the Company are received. Revenues from continuing operations recognized for three months ended September 30, 2022 and 2021 amounted to $1,314 and $8,127, respectively. Revenues from discontinued operations recognized for three months ended September 30, 2022 and 2021 amounted to $0 and $0, respectively. Revenues from continuing operations recognized for nine months ended September 30, 2022 and 2021 amounted to $1,314 and $55,651, respectively. Revenues from discontinued operations recognized for the nine months ended September 30, 2022 and 2021 amounted to $0 and $4,633, respectively.
Collaboration Revenue	Revenue recognition for collaboration agreements will require significant judgment. The Company’s assessments and estimates are based on contractual terms, historical experience and general industry practice. Revisions in these values or estimations have the effect of increasing or decreasing collaboration revenue in the period of revision. On August 21, 2020, the Company entered into a Distribution, License and Supply Agreement (“License Agreement”) with Empowered Diagnostics, LLC (“Empowered Diagnostics”). The License Agreement provides Empowered Diagnostics with a right to commercialize The Company’s products worldwide with the exception of Mexico. Under the License Agreement, the company is responsible for applying for and obtaining necessary regulatory approvals in the US and EU, as well as marketing, sales and distribution of the products. Empowered Diagnostics will pay a transfer price for all licensed products, and upon achievement of certain regulatory and sales milestones, the Company may receive payments from Empowered Diagnostics equal to 8% of the monthly gross revenue. Agreement continues until terminated by mutual consent or uncorrected breach. This agreement with Empowered Diagnostics was terminated in February 2022 The Company did not recognize any revenue from this agreement,
Grant Income	In 2021 the Company has received government grants to drive its research and development efforts. Through these government grants, the government has provided funding for the Company to perform research and development activities which will assist in developing its products. The Company believes the government entities funding these grants are interested in the Company advancing its underlying technologies through research activities and not providing incentives for hiring employees or building facilities that would suggest that the grant monies are not for specific research activities. In determining how to classify the monies received under government grants, the Company acknowledges that there is no specific guidance under US GAAP and that the FASB and AICPA have often drawn upon the guidance in IAS 20 for classification. In considering the alternatives provided by IAS 20 for the presentation of these grants in the Company’s financial statements, the Company believes that recognizing the government grant proceeds as a component of other revenue is a better reflection of the economics of the arrangements as the Company earns the funding through the performance of research and development which is not one of the Company’s primary business activities or central to its operations. The Company believes that presenting research and development funding from government grants, as other revenue provides consistency in our financial reporting. The Company also believes that this presentation clearly presents to users of its financial statements in one line the Company’s sources of funding from these grants. The Company notes that there are no contingencies associated with the receipt of or ability to retain the funds under the grant, other than undertaking and performing the related research and development activities. The Company recognizes funds received from contractual research and development services and from government grants as other revenue. These contracts and grants are not considered an ongoing major and central operation of the Company’s business. Our Income from Grants from Government for the three and nine months ended September 30, 2022 and 2021 was $0, $0 and $59,986, $279,981 respectively.
Cost of Sales	Cost of sales includes the purchase cost of products sold and all costs associated with getting the products to the customers including buying and transportation costs. Cost of sales all related to discontinued operations.
Shipping Costs	Shipping and handling costs billed to customers will be recorded in sales. Shipping costs incurred by the company are recorded in general and administrative expenses. Shipping costs all related to discontinued operations.
Fair Value Measurements	The Company applies the guidance that is codified under ASC 820-10 related to assets and liabilities recognized or disclosed in the financial statements at fair value on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The Company’s financial instruments are cash and cash equivalents, accounts receivable, accounts payable, notes payable, and long-term debt. The recorded values of cash and cash equivalents and accounts payable approximate their fair values based on their short-term nature. The recorded values of notes payable and long-term debt approximate their fair values, as interest approximates market rates. ASC 820-10 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820-10 requires valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows: Fair Value Hierarchy Inputs to Fair Value Methodology Level 1 Quoted prices in active markets for identical assets or liabilities Level 2 Quoted prices for similar assets or liabilities; quoted markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the financial instrument; inputs other than quoted prices that are observable for the asset or liability; or inputs that are derived principally from, or corroborated by, observable market information Level 3 Pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption is unobservable or when the estimation of fair value requires significant management judgment All items required to be recorded or measured on a recurring basis are based upon Level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement The Company recognizes its derivative liabilities as Level 3 and values its derivatives using the methods discussed below. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed are that of volatility and market price of the underlying common stock of the Company. The Company’s acquired goodwill with a carrying amount of $2,458,233 were written down to zero, resulting in an impairment charge of $2,458,233, which was included in earnings for the period ending September 30, 2020. In-process Research and Development with a carrying amount of $5,848,219 was written down to its implied fair value of zero, resulting in an impairment charge of $5,848,219, which was included in earnings for the period ending December 31, 2021. Items recorded or measured at fair value on a recurring basis in the accompanying condensed consolidated financial statements consisted of the following items as of September 30, 2022 Total Level 1 Level 2 Level 3 Derivative liabilities $ 1,995,618 $ - $ - $ 1,995,618
Convertible Instruments	The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities.” Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of “Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.
Income Taxes	The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including reversals of any existing taxable temporary differences, projected future taxable income, tax planning strategies, and the results of recent operations. If the Company determines that it would be able to realize a deferred tax asset in the future in excess of any recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25. No amounts were accrued for the payment of interest and penalties as of September 30, 2022 and December 31, 2021 respectively. The Company is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the Nine months ended September 30, 2022 and 2021 respectively. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “Cares Act”) was enacted. The CARES Act included loans and grants to certain businesses, and temporary amendments to the Internal Revenue Code which changed net loss carryforward and back provisions and the business interest expenses limitation. Under the CARES Act provisions, the most relevant income tax considerations to Oncocyte relate to the amounts received under the Paycheck Protection Program loan program and the possible forgiveness of those loans by the SBA. On December 21, 2020, the U.S. president has signed into law the “Consolidated Appropriations Act, 2021” which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans can deduct regular business expenses that are paid for with the loan proceeds for federal tax purposes. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant.
Concentrations of Credit Risk	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company had $0 and $0 allowance for doubtful accounts at September 30, 2022 and 2021, respectively and had $0 accounts receivable at September 30, 2022 and $0 at December 31, 2021.
Net Loss per Common Share	Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-dilutive. There were common share equivalents 47,140,220 at September 30, 2022 and 30,119,877 at December 31, 2021. For the three and nine months ended September 30, 2022 and 2021 respectively these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share.
Stock Based Compensation	All stock-based payments to employees and to nonemployee directors for their services as directors, including any grants of restricted stock and stock options, are measured at fair value on the grant date and recognized in the statements of operations as compensation or other expense over the relevant service period. Stock-based payments to nonemployees are recognized as an expense over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable the measurement date is the date the award is issued. The Company accounts for stock options issued to non-employees based on the estimated fair value of the awards using the Black-Scholes option pricing model in accordance with ASC 505-50, Equity-Based Payment to Non-employees
Research and Development	The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. For the three months and Nine months ended September 30, 2022 and 2021 the Company incurred research and development expenses of $29,722, $109,086 and $67,263, $216,282 respectively from continuing operations, respectively. For the three months and Nine months ended September 30, 2022 and 2021 the Company incurred research and development expenses of $0, $0 and $0, $0 from discontinued operations, respectively. The Company has entered into various agreements with CROs. The Company’s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.
Recently Issued Accounting Standards	Accounting Standards Implemented Since December 31, 2020 ASC Update 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update affect all entities that issue freestanding written call options that are classified in equity. Specifically, the amendments affect those entities when a freestanding equity-classified written call option is modified or exchanged and remains equity classified after the modification or exchange. The amendments that relate to the recognition and measurement of EPS for certain modifications or exchanges of freestanding equity-classified written call options affect entities that present EPS in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in this Update do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic. That is, accounting for those instruments continues to be subject to the requirements in other Topics. The amendments in this Update do not affect a holder’s accounting for freestanding call options. ASC Update No. 2020-10 In October 2020, the FASB issued ASC Update No. 2020-10, Codification Improvements. Update No. 2020-10 amends a wide variety of Topics in the Codification in order to improve the consistency of the Codification and the application thereof, while leaving Generally Accepted Accounting Principles unchanged. ASC Update No. 2020-06 In August 2020, the FASB issued ASC Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in Update No. 2020-06 simplify the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity’s own equity Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2022
SIGNIFICANT ACCOUNTING POLICIES
Schedule of Property and Equipment Relating to Continuing Operations	September 30, 2022 December 31, 2021 Equipment of continuing operations $ 183,992 $ 175,283 Less: accumulated depreciation 81,923 58,473 $ 102,069 $ 116,810
Schedule of Intangible Assets	September 30, December 31, 2022 2021 Patents $ 250,000 $ 250,000 Licenses 4,270,000 4,270,000 4,520,000 4,520,000 Less: accumulated amortization 431,960 136,127 $ 4,088,040 $ 4,383,873
Estimated Aggregate Amortization Expense	2022 2023 2024 2025 2026 and thereafter Amortization expense $ 98,656 $ 394,450 $ 394,450 $ 394,450 $ 2,806,034
Derivative Liabilities Measured at Fair Value on Recurring Basis	Total Level 1 Level 2 Level 3 Derivative liabilities $ 1,995,618 $ - $ - $ 1,995,618

PREPAID EXPENSES (Tables)

PREPAID EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2022
PREPAID EXPENSES
Schedule of Prepaid Expenses	September 30, December 31, 2022 2021 Prepaid insurance $ 65,390 $ 59,116 Prepaid services - 104,445 $ 65,390 $ 163,561

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2022
CONVERTIBLE NOTES PAYABLE
Schedule of Convertible Note Payable of Related Party	September 30, December 31, 2022 2021 Convertible note payable, due on November 1, 2026, interest at 3.5% p.a. $ 4,000,000 $ 4,000,000 Accrued interest 261,537 299,037 Convertible note payable, net $ 4,261,537 $ 4,299,037
Schedule of Convertible Notes Payable, Shareholder	September 30, December 31, 2022 2021 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. $ 484,478 $ 484,478 Convertible Note payable, due on October 1, 2022, interest at 6% p.a. - 1,110,000 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. 500,000 500,000 Convertible note payable, due on February 10, 2032, interest at 3.0% p. a. 1,150,000 - Convertible note payable, due on December 31, 2034, interest at 3% p.a. 190,000 190,000 Convertible Note payable due January 27, 2032 interest at 3% p.a. 367,931 Accrued interest (The accrued interest and principal are both included in the captions titled “convertible note payable” in the balance sheet) 252,820 209,685 Total 2,945,229 2,494,163 Less: unamortized debt discount/finance premium costs (1,629,876 ) (605,639 ) Convertible note payable, net $ 1,315,353 $ 1,888,524

DERIVATIVE LIABILITIES (Tables)

DERIVATIVE LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2022
DERIVATIVE LIABILITIES
Summary of Changes in Fair Value of Company's Level 3 Financial Liabilities	Balance, December 31, 2021 $ - Issuance of convertible note payable 2,641,846 Derivative liabilities on settlement of note transferred to gain on settlement (227,459 ) Mark to market (418,769 ) Balance, September 30, 2022 $ 1,995,618

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2022
STOCK OPTIONS AND WARRANTS
Schedule of Stock Option Activity	Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2020 10,300,000 $ 0.36 Granted 2,960,715 0.60 Exercised (300,000 ) 0.35 Expired or canceled (2,000,000 ) 0.75 Outstanding at December 31, 2021 10,960,715 $ 0.37 Granted 13,500,000 0.052 Exercised (500,000 ) 0.37 Balance September 30, 2022 23,960,715 $ 0.19
Schedule of Options under Stock Option Plan	Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.19 23,960,715 9.0 $ 0.19 17,141,095 $ 0.19 Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.36 10,960,715 8.5 $ 0.37 8,094,046 $ 0.37
Schedule of Assumptions to Determine Value of Share-based Compensation for Options	September 30, December 31, 2022 2021 Expected life (years) 10 10 Risk-free interest rate (%) 3.03 1.74 Expected volatility (%) 229 190 Dividend yield (%) - - Weighted average fair value of shares at grant date $ 0.19 $ 1.74
Schedule of Warrants	Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2020 - $ - Granted 3,025,000 0.71 Forfeited/Cancelled - - Exercised - - Outstanding at December 31, 2021 3,025,000 $ 0.71 Granted 519,247 0.31 Exercised Outstanding at September 30, 2022 3,544,247 0.65

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	9 Months Ended
	Sep. 30, 2022
DISCONTINUED OPERATIONS
Summary of Results of Discontinued Operations	September 30, 2022 September 30, 2021 Net sales $ - $ - Total expenses $ - $ (4,633 ) Gain from sale of asset and liability $ - $ - Other (loss) income $ - $ - (Loss) income from discontinued operations $ - $ (4,633 ) September 30, 2022 September 30 2021 Net (loss) income from discontinued operations $ - $ (4,633 ) Adjustment of non-cash activities - - Decrease in accounts receivable - - Increase in inventory - - Increase in accounts payable and accrued expenses - - Net cash provided by (used in) operating activities $ - $ (4,633 ) Net cash provided by (used in) investing activities $ - $ - Net cash provided by (used in) financing activities $ - $ -

COMMITMENT AND CONTINGENCIES (T

COMMITMENT AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2022
OTHER COMMITMENTS
Summary of Right of Use Assets and Liabilities	Right-of-use assets $ 34,374 Lease liability obligations, current $ 34,374 Lease liability obligations, noncurrent Total lease liability obligations $ 34,374 Weighted-average remaining lease term 0.58 years Weighted-average discount rate 6 %
Summary of Lease Expenses	September 30, September 30, 2022 2021 Operating lease expense $ 15,000 * $ 14,421 Short-term lease expense 12,932 4,166 Total lease expense $ 27,932 $ 18,587 September 30, September 30, 2022 2021 Operating lease expense $44,416 ** $ 43,122 Short-term lease expense 45,292 11,545 Total lease expense $89,708 ** $ 54,667
Schedule of Future Minimum Rental Payments for Operating Leases	2022 $ 15,000 2023 20,000 Total minimum payments 35,000 Less: amount representing interest (626 ) Total $ 34,374

ORGANIZATION (Details Narrative

ORGANIZATION (Details Narrative) - shares	Jan. 06, 2022	May 11, 2015	Jan. 10, 2022
ORGANIZATION
Acquisition ownership percentage		100%	16.40%
Acquisition of common stock shares		5,826,706
Organization description	the record holder of 500,000 shares of the Company’s Series C Preferred Stock, representing 100% of the 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are entitled to cast a vote for election of up to four Series C Directors, whether by shareholder meeting

ACQUISITION OF INTELLECTUAL P_2

ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC LLC (Details Narrative) - USD ($)		1 Months Ended		9 Months Ended
	May 11, 2015	Aug. 26, 2021	Jul. 29, 2021	Sep. 30, 2022	Dec. 31, 2021
Patents				$ 250,000	$ 250,000
Sellers liabilities to pay				(8,859,093)	$ (7,661,635)
Acquisition of common stock shares	5,826,706
Tear Diagnostics LLC [Member]
Patents			$ 250,000
Purchase price			(210,000)
Monthly payments			30,000
Purchase Price acquisition				$ 4,520,000
Licenses fee		$ 4,270,000
Sellers liabilities to pay			$ (30,000)
Acquisition of common stock shares		7,000,000
Patents average ife				11 years 6 months 14 days

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)		1 Months Ended
	Mar. 11, 2019	Apr. 16, 2018	Sep. 30, 2022	Dec. 31, 2021
Working capital deficit			$ (2,914,013)
Accumulated deficit			(63,226,126)	$ (57,882,227)
Net cash provided by (used in) operating activities		$ 1,728,821
Stock Purchase Agreement [Member]
Share issued amount reduced	$ 400,000
Additional capital raised			$ 1,507,419	$ 1,610,538
Share sold during period		1,945,000

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
SIGNIFICANT ACCOUNTING POLICIES
Equipment of continuing operations	$ 183,992	$ 175,283
Less: accumulated depreciation	81,923	58,473
Property, Plant and Equipment, Net	$ 102,069	$ 116,810

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
SIGNIFICANT ACCOUNTING POLICIES
Patents	$ 250,000	$ 250,000
Licenses	4,270,000	4,270,000
Finite-Lived Intangible Assets, Gross	4,520,000	4,520,000
Less: accumulated amortization	431,960	136,127
Intangible Assets, Net	$ 4,088,040	$ 4,383,873

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Details 2)	Sep. 30, 2022 USD ($)
SIGNIFICANT ACCOUNTING POLICIES
2022	$ 98,656
2023	394,450
2024	394,450
2025	394,450
2026 and thereafter	$ 2,806,034

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES (Details 3)	Sep. 30, 2022 USD ($)
Derivative liabilities	$ 1,995,618
Level 1 [Member]
Derivative liabilities	0
Level 2 [Member]
Derivative liabilities	0
Level 3 [Member]
Derivative liabilities	$ 1,995,618

SIGNIFICANT ACCOUNTING POLICI_8

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash and cash equivalents	$ 0		$ 0
Acquisition from goodwill			2,458,233
Goodwill impairment charge			2,458,233
Amortization expense	98,612	$ 692,858	295,835	$ 1,333,954
Depreciation expense	8,133	6,935	23,451	20,119
Allowance for doubtful accounts	0	0	0	0
Accounts receivable	0		0		$ 0
Revenues from continuing operations		8,127	1,314	55,651
Revenues from discontinuing operations	0	0	0	4,633
Income from Grants from Government		0	$ 59,986	279,981
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			47,140,220		30,119,877
Research and Development Expense from continuing operation	29,722	67,263	$ 109,086	216,282
Research and Development Expense from discontinuing operation	$ 0	$ 0	0	$ 0
Acquired goodwill carrying amount			2,458,233
Impairment charge			$ 5,848,219		$ 5,848,219
One Customer [Member]
Concentrations percentage, revenue			100%		100%
Two Customer [Member]
Concentrations percentage, revenue		8%
Other Intangible Assets [Member]
Impairment charge			$ 5,966,452

PREPAID EXPENSES (Details)

PREPAID EXPENSES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
PREPAID EXPENSES (Details)
Prepaid insurance	$ 65,390	$ 59,116
Prepaid services	0	104,445
Prepaid expenses	$ 65,390	$ 163,561

PREPAID EXPENSES (Details Narra

PREPAID EXPENSES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
PREPAID EXPENSES (Details)
Amortization of prepaid insurance	$ 22,121	$ 105,353	$ 187,887	$ 216,158

PROMISSORY NOTE (Details Narrat

PROMISSORY NOTE (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Jul. 29, 2021
Notes Payble		$ 90,000		$ 90,000	$ 90,000		$ 210,000
Accrued interest		1,515		$ 1,515	$ 1,515
Maturity Date					Nov. 01, 2026
Interest Expense		57,481	$ 56,007		$ 1,629,355	$ 175,915
Loans Assumed	$ 128,375
Sapphire Biotech [Member]
Interest Expense	14,218
Loans Assumed	310,000
Debt Instrument, Face Amount	324,218
Debt Exchange Agreement [Member]
Debt Instrument, Interest Rate During Period				3%
Accrued interest	$ 363,178	$ 0		$ 0	$ 0
Strike price	$ 0.1075
Maturity Date	Jan. 27, 2032
Debt Exchange Agreement [Member] | Sapphire Biotech [Member]
Debt Instrument, Face Amount	$ 324,218
Debt Exchange Agreement 7 [Member] | Sapphire Biotech [Member]
Interest Expense	14,218
Loans Assumed	310,000
Debt Exchange Agreement 3 [Member] | Sapphire Biotech [Member]
Loans Assumed	$ 128,375
Convertible Preferred Stock Series B [Member]
Debt Instrument, Interest Rate During Period	6%

OTHER COMMITMENTS (Details Narr

OTHER COMMITMENTS (Details Narrative) - USD ($)		1 Months Ended				3 Months Ended		9 Months Ended			12 Months Ended
	Jan. 02, 2019	Apr. 30, 2020	Mar. 31, 2020	Sep. 25, 2018	Mar. 20, 2018	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2020	May 06, 2020	Dec. 31, 2019
Monthly bonus fee	$ 15,000
Consulting fees	$ 20,000
Implicit interest rate								5%
Indebtedness amount															$ 2,610,000
Issued and outstanding shares purchase percentage															100%
Common stock held in treasury															18,570,356
Issued and outstanding shares															500,000
Payment for issued and outstanding shares								$ 65,000
Restrictive shares issued during period						17,141,095	11,260,715	17,141,095	17,141,095	11,260,715	10,960,715	10,460,715	10,460,715	10,300,000		2,000,000
Compensation expenses						$ 517,180	$ 761,810		$ 888,313	$ 953,076
Severance cost								$ 102,387
S-8 Shares, shares						13,500,000
Mr Changoer [Member]
Consulting fees								0			$ 20,000
Restrictive shares issued during period					50,000
Compensation expenses					$ 235,000
Accrued severance payment in account payable											20,000
Severance cost								$ 20,000
Dr. Anastassov [Member]
Accrued severance payment in account payable											40,000
Severance cost		$ 20,000	$ 35,000
S-8 Shares, shares								150,000
Gross cash proceeds from the sale of shares in lieu of cash severance								$ 20,000
Monthly severance obligation								20,000
Gross proceeds from the sale of S-8 Shares								20,000
S-8 Shares, amount								15,000
Van Demme [Member]
Severance cost								5,000
Cash compensation				$ 20,000
Monthly clinical trial fee				$ 5,000
Accounts payable						$ 0		$ 0	$ 0		$ 0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)	1 Months Ended
	Mar. 17, 2020 USD ($)
Catlina Valencia [Member]
Accounts Payable, Related Parties, Current	$ 15,000
Dr. Sergei A. Svarovsky [Member]
Accounts Payable, Related Parties, Current	$ 15,000
Description of Related Party	The agreement can be terminated with 30 days’ notice by either party

DUE TO FIRST INSURANCE FUNDING

DUE TO FIRST INSURANCE FUNDING (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Jun. 25, 2022	Jun. 25, 2021	Jun. 25, 2020
DUE TO FIRST INSURANCE FUNDING (Details Narrative)
Insaurance renewal fee			$ 89,391		$ 93,357
Cash down payment			$ 8,776	$ 24,273	$ 18,671
Interest rate			4.92%	4.42%	4.60%
Insurance financing, payments			$ 8,957
Premium paid			$ 1,628	$ 1,797	$ 8,546
Total Outstanding amount	$ 53,698	$ 32,873

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument, Interest Rate, Stated Percentage		3.50%
Convertible notes payable due to shareholder
Debt Instrument, Face Amount	$ 4,000,000	$ 4,000,000
Accrued interest	261,537	299,037
Convertible note payable, net	$ 4,261,537	$ 4,299,037

CONVERTIBLE NOTES PAYABLE (De_2

CONVERTIBLE NOTES PAYABLE (Details 1) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Less: unamortized debt discount/finance premium costs	$ (1,629,876)	$ 605,639
Convertible Note Payable Net	1,315,353	1,888,524
Convertible note payable
Accrued interest (The accrued interest and principal are both included in the captions titled "convertible note payable" in the balance sheet)	252,820	209,685
Total	2,945,229	2,494,163
Convertible Note Payable 6 [Member]
Total	367,931	0
Convertible Note Payable 1 [Member]
Total	484,478	484,478
Convertible Note Payable 2 [Member]
Total	0	1,110,000
Convertible Note Payable 3 [Member]
Total	500,000	500,000
Convertible Note Payable 4 [Member]
Total	1,150,000	0
Convertible Note Payable 5 [Member]
Total	$ 190,000	$ 190,000

CONVERTIBLE NOTES PAYABLE (De_3

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)				1 Months Ended							3 Months Ended				9 Months Ended			12 Months Ended
	Feb. 10, 2022	Nov. 07, 2021	May 11, 2015	Feb. 22, 2022	Jan. 27, 2022	Nov. 24, 2021	Sep. 27, 2021	Mar. 17, 2020	Dec. 31, 2019	Oct. 20, 2016	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2019	Dec. 31, 2021	Jun. 07, 2021	Dec. 31, 2020	Jul. 21, 2020	May 01, 2020	May 01, 2019	Sep. 16, 2016
Interest expenses											$ 35,000		$ 35,000			$ 105,000	$ 105,000
Gain on change in derivative liabilities																(227,459)
Convertible note interest rate					1%																		3.50%
Cancellation of debt discount															$ 167,571
Loss on extinguishment											111,818	$ 154,292	0	$ 1,535,264	111,807	490,641	1,535,264
Conversion price per share							$ 0.25																$ 0.25
Strike price					$ 0.1075
Conversion price per share reduced from																							1.50
Stock modification price per share																							$ 0.13
Accrued interest		$ 28,578			$ 261,537						2,840				2,840	2,840			$ 299,037
Fair value prior to the amendment																							$ 4,000,000
Convertible note															175,000
Fair value of the Note and embedded derivatives after the amendment											4,000,000				4,000,000	4,000,000							$ 4,000,000
Loans Assumed									$ 128,375
Extinguishment of debt		$ 1,535,264
Total											$ 0				$ 0	$ 0			$ 1,126,919
Interest rate per annum																			6%
Common stock price per share											$ 0.0001				$ 0.0001	$ 0.0001			$ 0.0001
Convertible note beneficial conversion feature	$ 1,325,000
Acquisition of common share			5,826,706
Original maturity date																Nov. 01, 2026
Share issued in settlement of debt		1,725,439													5,665,636
Share issued in settlement of debt															$ 349,535
Loss on conversion															171,695
Interest rate per annum																			3.50%
Amortization of debt discount																$ 132,521	220,578
Restricted common stock issued for accrued interest											13,500,000
Interest Expense											$ 57,481		56,007			1,629,355	175,915
Secured Convertible Debt [Member]
Convertible Debt											4,261,537				4,261,537	4,261,537			$ 4,299,037
Accrued interest											286,537				286,537	286,537			299,037
Secured Convertible Debt 1 [Member]
Convertible Debt											586,611				586,611	586,611			573,612
Accrued interest											102,133				102,133	102,133			89,134
Secured Convertible Debt 2 [Member]
Convertible Debt											605,630				605,630	605,630			592,215
Accrued interest											105,630				105,630	105,630			92,215
Secured Convertible Debt 3 [Member]
Convertible Debt											205,690				205,690	205,690			201,416
Accrued interest											15,690				15,690	15,690			11,416
Secured Convertible Debt 5 [Member]
Convertible Debt											0				0	0			1,126,919
Accrued interest											0				0	0			16,919
Secured Convertible Debt 4 [Member]
Convertible Debt											0				0	0			0
Accrued interest											0				0	0			0
Short Term Promissory Notes [Member]
Original maturity date	Mar. 10, 2022
Interest rate per annum	1.50%
Short term promissory notes face value	$ 250,000
Short term promissory notes	500,000
Convertible Note Purchase Agreement
Convertible note interest rate					3%					3.50%															3.50%
Conversion price per share										$ 0.2201										$ 0.2201		$ 0.37			$ 0.2201
Accrued interest																				$ 82,707
Extinguishment of debt																				1,535,264
Common stock price per share									$ 1.90									$ 1.90
Convertible note beneficial conversion feature										$ 499,318
Original maturity date										Oct. 01, 2029								Dec. 31, 2034
Total									$ 190,000	$ 250,000								$ 190,000		$ 500,000		$ 609,835
Interest rate per annum									3%									3%				3.50%
Discount amortized amount using effective interest method									$ 190,000									$ 190,000
Sale of capital stock, percentage																		5%
Investor Paid in Cash										500,000
Inventory purchase																									$ 5,000,000
Secured convertible note										1,000,000															$ 850,000
Secured Notes Total, amount										500,000
Common stock conversion						1,725,439														2,647,464
Secured promissory notes										250,000
Promissory notes										$ 500,000
Additionally secured number of shares										10,486,303
Additionally secured number of shares, value										$ 858,828
Debt extinguishment due to change in fair values percentage																						10%
Common stock conversion amount						$ 28,578
Loss on conversion expense					$ 154,292	$ 51,763
Convertible Debt																			0
Purchase Agreement with GS Capital LLC
Conversion price per share							$ 0.25
Total	1,110,000						$ 1,110,000
Original maturity date							Sep. 29, 2022
Interest rate per annum							6%
Accrued interest	21,863			$ 21,863
Conversion price average discount percentage							30 percent
Restricted common stock issued for accrued interest				173,390
Restricted share issued value				$ 32,944
Loss on extinguishment of debt				11,081
Penalty for early repayment				$ 133,200
Closing price of share				$ 0.19
Original issue discount							$ 100,000
Bridge financing fees							100,000
Legal costs							$ 30,000
Share Exchange Agreement
Total								$ 190,000
Convertible note beneficial conversion feature								$ 190,000
Common stock conversion								6,000,000
Unsecured Convertible Notes
Cancellation of debt discount											46,441		$ 17,456
Total	$ 1,325,000
Original maturity date	Feb. 10, 2032
Interest rate per annum	6%
Discount amortized amount using effective interest method											1,629,876				1,629,876	1,629,876			605,639
Amortization of debt discount																132,521	$ 220,578
Convertible notes face value in exchange for cash	$ 1,325,000
Terms of conversion	is convertible, in whole or in part, at any time by the holder, into restricted shares of the Company’s common stock at a conversion price equal to the lesser of $0.08125 or 70% of the average of the two lowest closing prices of the Company’s common stock in the ten trading days preceding any particular conversion, provided, the holder is prohibited from converting the convertible note, or portion thereof, if such conversion would result in beneficial ownership by the holder and its affiliates of more than 4.999% of Company’s issued and outstanding common stock as of the date of the conversion. A debt discount was recorded related to beneficial conversion feature in connection with this convertible note of $1,325,000
Blake N. Schroeder
Total	$ 25,000
Kannaway [Member]
Accounts Receivable, after Allowance for Credit Loss, Noncurrent																					$ 75,074
Sapphire Biotech [Member]
Loans Assumed									310,000
Interest Expense									14,218
Debt Instrument, Face Amount									$ 324,218									$ 324,218
Debt Exchange Agreement [Member]
Original maturity date									Jan. 27, 2032
Accrued interest									$ 363,178		$ 375,427				$ 375,427	$ 375,427		363,178	$ 0
Debt Exchange Agreement [Member] | Medical Marijuana Inc [Member]
Accrued interest																								$ 60,278
Debt Exchange Agreement [Member] | Sapphire Biotech [Member]
Debt Instrument, Face Amount									$ 324,218									$ 324,218

DERIVATIVE LIABILITIES (Details

DERIVATIVE LIABILITIES (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)
DERIVATIVE LIABILITIES (Details)
Balance, beginning	$ 0
Issuance of convertible note payable	2,641,846
Gain on change in derivative liabilities	(227,459)
Mark to market	(418,769)
Balance June 30, 2022	$ 1,995,618

DERIVATIVE LIABILITIES (Detai_2

DERIVATIVE LIABILITIES (Details Narrative) - USD ($)		9 Months Ended
	Feb. 10, 2022	Sep. 30, 2022	Sep. 30, 2022
Fair value of embedded derivatives	$ 2,641,846	$ 1,995,618	$ 1,995,618
Beneficial conversion feature	1,325,000
Non-cash interest expenses	$ 1,316,846
Gain on change in fair value of derivative liabilities			$ 418,769
Dividend yield
Derivative liability measurment input assumption	0%	0%	0%
Volatility
Derivative liability measurment input assumption	163.09%	162.72%	162.72%
Risk Free Interest Rate
Derivative liability measurment input assumption	2.03%	2.32%	2.32%
Expected Term
Derivative liability measurment input assumptions	10 years	9 years 10 months 9 days

STOCK INCENTIVE PLAN (Details N

STOCK INCENTIVE PLAN (Details Narrative) - USD ($)				1 Months Ended			3 Months Ended		9 Months Ended
	Sep. 08, 2021	Aug. 02, 2021	Sep. 04, 2020	Aug. 17, 2021	May 20, 2021	May 29, 2015	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Stock available for issuance							9,635,350		9,635,350		9,806,000
Share Based Compensation expense							$ 517,180	$ 761,810	$ 888,313	$ 953,076
Option granted purchase shares									13,500,000
Purchase price of stock option									$ 0.052
2015 Stock Incentive Plan [Member]
Common stock issued under registration statement on Form S-8						10,000,000
Increase of issuance shares					20,000,000
Bijan Pedram [Member]
Option granted purchase shares		100,000
Purchase price of stock option		$ 0.67
Stock option vesting description		25% of the Option shares will be vested upon the one anniversary of the vesting commencement day and the balance of the option shares will be vested of thirty-six (36) successive equal monthly in the first anniversary of the vesting commencement day.
Laura M. Periman Medical [Member]
Option granted purchase shares		100,000
Purchase price of stock option		$ 0.64
Stock option vesting description		50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day.
Joseph Tauber [Member]
Option granted purchase shares	1
Purchase price of stock option	$ 0.622
Stock option vesting description	25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day.
Jeft Busby [Member]
Option granted purchase shares				1,000,000
Purchase price of stock option				$ 0.60
Stock option vesting description				25% of the Option shares will be vested upon the two anniversaries of the vesting commencement day, 25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day.
Kelly K. Nichols [Member]
Purchase price of stock option			$ 0.62
Stock option vesting description			50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day.
Option granted purchase shares			100,000

STOCKHOLDERS DEFICIT (Details N

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)							1 Months Ended				2 Months Ended	3 Months Ended					7 Months Ended	9 Months Ended			12 Months Ended
	Jul. 14, 2022	May 04, 2022	Dec. 13, 2021	Nov. 07, 2021	Oct. 12, 2021	May 11, 2015	Jan. 31, 2022	Oct. 18, 2021	Jun. 30, 2021	Feb. 20, 2019	Sep. 30, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Dec. 13, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Feb. 20, 2022	Jan. 27, 2022	Jan. 11, 2022	Jul. 29, 2021	May 14, 2021	Mar. 31, 2021	Mar. 18, 2021	Aug. 18, 2016	Aug. 17, 2016
Accrued interest				$ 28,578								$ 2,840						$ 2,840	$ 2,840		$ 299,037		$ 261,537
Settlement debt				$ 638,412
Pereferred stock par value												$ 0.0001						$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock share authorized												5,000,000						5,000,000	5,000,000		5,000,000
Undesignated preferred shares outstanding											0	0			0			0	0	0
Undesignated preferred shares issued											0	0			0			0	0	0
Common stock share authorized												300,000,000						300,000,000	300,000,000
Common stock price per share												$ 0.0001						$ 0.0001	$ 0.0001		$ 0.0001
Common stock shares outstanding												185,441,917						185,441,917	185,441,917		138,099,981
Share issued during period							519,247
Share issued during period, value		$ 135,000					$ 75,000
Warrants to purchase shares							519,247
Warrant exercise price							$ 0.315
Stock issued for services							302,115
Stock issued for services, value			$ 100,000				$ 100,000							$ 79,500		$ 776,500
Common stock shares issued												185,441,917						185,441,917	185,441,917		185,441,917
Share issued in settlement of debt				1,725,439														5,665,636
Convertible debt amount												$ 177,840						$ 177,840	$ 177,840
Warrants exercisable period							3 years
Finders fees paid																					$ 20,000
Capital raised																					16,000
Gross proceeds																											$ 434,000
Acquisition of common share						5,826,706
Common stock shares sold												18,545						18,545	18,545		13,811
Additional capital												58,752,209						58,752,209	58,752,209		$ 51,000,166
Extinguishment of debt				$ 1,535,264
Loss on extinguishment												111,818	$ 154,292		$ 0	1,535,264		111,807	490,641	$ 1,535,264
Cancellation of debt discount																		$ 167,571
Stock issued for services, value														$ 79,500	1,111,900	776,500
GS Capital [Member]
Stock issued for services					118,000
Stock issued for services, value					$ 57,466											776,500
Meetings And Conferences [Member]
Share issued during period																		500,000
Share issued during period, value																		$ 79,500
Registration Statement on Form S-1 [Member]
Share issued during period																	500,000	2,227,638
Share issued during period, value																	$ 129,274	$ 138,991
Additional capital									$ 103,688							103,688
Restrickted share issued value									$ 332,500		$ 129,724				$ 129,724	$ 332,500				$ 129,724
Restricted share issued									500,000		262,400				262,400	500,000				262,400
Subscription receivable																		$ 60,064
Cash received																	$ 129,274
Actual proceeds									$ 228,812							$ 228,812
Settlement [Member]
Share issued during period																		173,390
Share issued during period, value																		$ 32,944
loss on settlement																		11,081
Gain on cancellation of derivative liability																		$ 227,459
Equity Purchase Agreement [Member]
Share issued during period																		1,000,000
Share issued during period, value	$ 60,064																	$ 881,255
Common stock shares sold	$ 30,000,000																									$ 10,000,000
Subscription amount																		60,064
Issued and outstanding shares percentage	4.99%																									4.99%
Investment Amount, Percentage not more than	300%																									500%
Share additional																		62,064
Proceeds																		2,000,000
Equity Purchase Agreement [Member] | Minimum [Member]
Investment Amount	$ 10,000																									$ 10,000
Equity Purchase Agreement [Member] | Maximum [Member]
Investment Amount	$ 250,000																									$ 1,000,000
Advanced Tear Diagnostics [Member]
Share issued during period											7,000,000
Share issued during period, value											$ 4,270,000
Acquisition of common share							7,000,000
Convertible Notes [Member]
Accrued interest									582,707			$ 2,840				582,707		2,840	$ 2,840
Extinguishment of debt									1,535,264							1,535,264
Loss on extinguishment																		111,807
Cancellation of debt discount																		$ 167,571
Restrickted share issued value									$ 2,117,971							$ 2,117,971
Restricted share issued									2,647,464							2,647,464
Options [Member]
Warrant exercise price																					$ 0.126			$ 0.126
Common stock shares issued																					196,438			500,000
Option exercised																					300,000			282,759
Convertible Preferred Stock Series C
Pereferred stock par value												$ 0.0001						$ 0.0001	$ 0.0001		$ 0.0001
Designated shares																													500,000	500,000
Vote per share																														$ 100
Blank Check [Member]
Preferred stock share authorized												4,000,000						4,000,000	4,000,000
Series C Convertible Preferred Stock [Member] | MJNA Investment Holdings, LLC [Member]
Undesignated preferred shares issued																													500,000
Share issued value																													$ 65,000
Common stock to be issued [Member]
Warrants to purchase shares									714,285							714,285
Warrant exercise price									$ 0.80		$ 0.60				$ 0.60	$ 0.80				$ 0.60
Common stock shares issued																												108,965
Warrants exercisable period									3 years
Restricted share issued for services																												488,428
Common stock, value																												$ 291,974
Common stock shares issued value																												$ 66,974
Stock Purchase Agreement [Member]
Share issued during period								175,000										13,861,004
Share issued during period, value								$ 52,500										$ 350,000
Common stock shares issued														624,290
Gross proceeds														$ 55,000
Restrickted share issued value											$ 1,111,900				$ 1,111,900					$ 1,111,900					$ 50,000
Restricted share issued											1,415,554				1,415,554					1,415,554					122,000
George Anastassov and Lekhram Changoer [Member]
Share issued during period																		891,610
debt totaled												$ 60,000						$ 60,000	$ 60,000
Settlement																		$ 4,196
Shares in settlement																		3,544,247
Loss																		$ 226,171
Warrant Stock Purchase Agreement [Member]
Share issued during period									519,828
Share issued during period, value									$ 152,500
Warrants to purchase shares									175,000		1,060,715				1,060,715	175,000				1,060,715
Warrant exercise price									$ 0.75		$ 0.60				$ 0.60	$ 0.75				$ 0.60							$ 0.75
Common stock shares issued									1,234,113		1,060,715				1,060,715	1,234,113				1,060,715
Warrants exercisable period											3 years
Cash received									$ 402,500		$ 297,000
Warrants to purchase shares of common stock																											900,000
Consulting Agreement [Member]
Restrickted share issued value									$ 1,114,351							$ 1,114,351					$ 100,000						$ 1,712,500
Restricted share issued									792,389							792,389
Purchase Agreement [Member] | Series C Convertible Preferred Stock [Member] | AXIM Biotechnologies Inc [Member]
Share sold during period										500,000
Purchase price										$ 500,000
Check payable amount										$ 65,000
Promissory note, face value																						$ 435,000

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details) - $ / shares	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
DUE TO FIRST INSURANCE FUNDING
Options Outstanding, Beginning	10,960,715		10,300,000
Granted		(13,500,000)	(2,960,715)
Exercised		(500,000)	(300,000)
Expired or canceled			(2,000,000)
Options Outstanding, Ending		23,960,715	10,960,715
Weighted Average Exercise Price, beginning	$ 0.19		$ 0.36
Granted		$ 0.052	0.60
Exercised		0.37	0.35
Weighted Average Exercised price ending		$ 0.19	0.37
Expired or canceled			$ 0.75

STOCK OPTIONS AND WARRANTS (D_2

STOCK OPTIONS AND WARRANTS (Details 1) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
DUE TO FIRST INSURANCE FUNDING
Options Number exercisable, begenning	17,141,095	8,094,046
Options Outstanding, Ending	23,960,715	10,960,715
Number Exercisable Number of Share	23,960,715	8,094,046
Weighted Average Exercise Price, beginning	$ 0.19	$ 0.36
Options Outstanding, Ending	17,141,095	10,960,715
Weighted Average Remaining Contractual Life	9 years	8 years 6 months
Options Exercisable Weighted Average Exercise Price	$ 0.19	$ 0.37
Weighted Average Exercised price ending	$ 0.19	$ 0.37

STOCK OPTIONS AND WARRANTS (D_3

STOCK OPTIONS AND WARRANTS (Details 2) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
DUE TO FIRST INSURANCE FUNDING
Expected life (years)	10 years	10 years
Risk-free interest rate (%)	3.03%	1.74%
Expected volatility (%)	229%	190%
Dividend yield (%)	0%	0%
Weighted average fair value of shares at grant date	$ 0.19	$ 1.74

STOCK OPTIONS AND WARRANTS (D_4

STOCK OPTIONS AND WARRANTS (Details 3) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Options Outstanding, Beginning		10,300,000
Granted	13,500,000	2,960,715
Options Outstanding, Ending	17,141,095	10,960,715
Weighted Average Exercise Price, beginning		$ 0.36
Granted, Weighted Average Exercise Price	$ 0.052	0.60
Forfeited/Cancelled, , Weighted Average Exercise Price		0.75
Exercised, Weighted Average Exercise Price	$ 0.37	0.35
Weighted Average Exercise Price, ending		$ 0.19
Warrants
Options Outstanding, Beginning		0
Granted	519,247	3,025,000
Forfeited/Cancelled		0
Exercised		$ 0
Options Outstanding, Ending	3,544,247	3,025,000
Weighted Average Exercise Price, beginning		$ 0
Granted, Weighted Average Exercise Price	$ 0.31	0.71
Forfeited/Cancelled, , Weighted Average Exercise Price		0
Exercised, Weighted Average Exercise Price		0
Weighted Average Exercise Price, ending	$ 0.65	$ 0.71

STOCK OPTIONS AND WARRANTS (D_5

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
DUE TO FIRST INSURANCE FUNDING
Stock-based compensation expense	$ 517,180	$ 88,313	$ 761,810	$ 953,076
Restricted common stock issued for accrued interest	13,500,000
Fair Value	$ 675,000

DISCONTINUED OPERATIONS (Detail

DISCONTINUED OPERATIONS (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
DISCONTINUED OPERATIONS
Net sales	$ 0	$ 0
Total expenses	0	(4,633)
Gain from sale of asset and liability	0	0
Other loss (income)	0	0
(Loss) income from discontinued operations	0	(4,633)
Net (loss) income from discontinued operations	0	(4,633)
Adjustment of non-cash activities	0	0
Decrease in accounts receivable	0	0
Increase in inventory	0	0
Increase in accounts payable and accrued expenses	0	0
Net cash provided by (used in) operating activities	4,633	0
Net cash provided by (used in) investing activities	0	0
Net cash provided by (used in) financing activities	$ 0	$ 0

DISCONTINUED OPERATIONS (Deta_2

DISCONTINUED OPERATIONS (Details Narrative)	9 Months Ended
	Sep. 30, 2022 USD ($)
DISCONTINUED OPERATIONS
Purchase price for acquisition	$ 2,609,100

COMMITMENT AND CONTINGENCIES (D

COMMITMENT AND CONTINGENCIES (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
OTHER COMMITMENTS
Right-of-use assets	$ 34,374	$ 76,871
Lease liability obligations, current	34,374
Total lease liability obligations	$ 34,374
Weighted-average remaining lease term	6 months 29 days
Weighted-average discount rate	6%

COMMITMENT AND CONTINGENCIES _2

COMMITMENT AND CONTINGENCIES (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
OTHER COMMITMENTS
Operating Lease, Expense	$ 15,000	$ 14,421	$ 44,416	$ 43,122
Short-term lease expense	12,932	4,166	45,292	11,545
Total lease expense	$ 27,932	$ 18,587	$ 89,708	$ 54,667

COMMITMENT AND CONTINGENCIES _3

COMMITMENT AND CONTINGENCIES (Details 2)	Sep. 30, 2022 USD ($)
OTHER COMMITMENTS
2022	$ 15,000
2023	20,000
Total minimum payments	35,000
Less: amount representing interest	(626)
Total	$ 34,374

COMMITMENT AND CONTINGENCIES _4

COMMITMENT AND CONTINGENCIES (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended		9 Months Ended
	Jan. 02, 2019	Sep. 15, 2022	Apr. 24, 2017	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Monthly base rent						$ 4,854
operating lease expens				$ 27,932		89,708
Maintenance charges				15,644		45,292
License fee		$ 150,000
Research and development expenses						284,869
Grant income received						$ 279,981
Implicit interest rate						5%
Monthly base rent				15,000	$ 14,421	$ 44,416		$ 43,122
Research and development expenses				$ 29,722	$ 67,263		$ 109,086	$ 216,282
John W. Huemoeller [Member]
Increase salary per month	$ 35,000
Common stock granted purchase shares	2,000,000
Vesting percentage	50%
CFO [Member]
Increase salary per month			$ 3,000
Sponsored Research Agreement [Member]
Research and development expenses						150,468
3rd year [Member]
Monthly base rent						$ 5,000
Stock Purchase Agreement [Member]
Implicit interest rate						6%
Monthly base rent						$ 4,713
Salary	$ 10,000
Small business awarded						$ 395,880

NOTES RECEIVABLE (Details Narra

NOTES RECEIVABLE (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Aug. 16, 2022	Sep. 30, 2022	Jan. 27, 2022	Dec. 31, 2021	Nov. 07, 2021
Severence cost		$ 102,387
Accrued interest		2,840	$ 261,537	$ 299,037	$ 28,578
Purchase of Promissory Noteand Forbearance Agreement Member
Accrued interest		0		1,701
Proceeds from shares	135,000
Note Receivable		0		$ 102,567
Carrying value received		102,567
Issued shares of common stock pursuant to S-1 for cash		$ 32,433
Discription		face value of $350,000 and a remaining balance due of approximately $100,000 (the “Note”). The purchase price for the Note was $100,000 payable by the Company issuing Seller One Million (1,000,000) restricted shares of the Company’s Common Stock. Effective May 6, 2020, the Company and Maker entered into a Forbearance Agreement whereby the Company agreed to forbear from making any collection efforts on the Note for a period of 24 months so long as Maker has not breached the Separation Agreement. Following 24 months

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	1 Months Ended
	Oct. 27, 2022 shares
Subsequent Event [Member]
Stock issued for cash, share	1,000,000